[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 269
1. Perez-Campo FM, Borrow J, Kouskoff V, Lacaud G: The histone acetyl transferase activity of monocytic leukemia zinc finger is critical for the proliferation of hematopoietic precursors. Blood; 2009 May 14;113(20):4866-74
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The histone acetyl transferase activity of monocytic leukemia zinc finger is critical for the proliferation of hematopoietic precursors.
  • The monocytic leukemia zinc finger (MOZ) gene encodes a large multidomain protein that contains, besides other domains, 2 coactivation domains for the transcription factor Runx1/acute myeloid leukemia 1 and a histone acetyl transferase (HAT) catalytic domain.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1996 Sep;14(1):33-41 [8782817.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3444-9 [8622955.001]
  • [Cites] Development. 1998 Feb;125(4):725-32 [9435292.001]
  • [Cites] Blood. 1998 May 1;91(9):3127-33 [9558366.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Aug;113(1):70-2 [10459350.001]
  • [Cites] J Biol Chem. 1999 Oct 1;274(40):28528-36 [10497217.001]
  • [Cites] Nature. 2004 Dec 2;432(7017):625-30 [15577911.001]
  • [Cites] Trends Cardiovasc Med. 2004 Nov;14(8):314-7 [15596108.001]
  • [Cites] Cell. 2005 Sep 23;122(6):947-56 [16153702.001]
  • [Cites] Mol Cell. 2006 Jan 6;21(1):51-64 [16387653.001]
  • [Cites] Genes Dev. 2006 May 1;20(9):1175-86 [16651658.001]
  • [Cites] Genes Dev. 2006 May 15;20(10):1321-30 [16702405.001]
  • [Cites] J Immunol. 2006 Oct 15;177(8):5420-9 [17015728.001]
  • [Cites] J Neurosci. 2006 Nov 1;26(44):11359-70 [17079664.001]
  • [Cites] Science. 2007 Aug 3;317(5838):620-2 [17673651.001]
  • [Cites] Exp Cell Res. 2007 Oct 1;313(16):3604-15 [17765223.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6697-714 [17934479.001]
  • [Cites] Cell. 2007 Nov 16;131(4):633-6 [18022353.001]
  • [Cites] Mol Cell Proteomics. 2008 Mar;7(3):459-72 [18045800.001]
  • [Cites] Leukemia. 2008 Mar;22(3):663-5 [17805331.001]
  • [Cites] Development. 2008 Apr;135(8):1525-35 [18339678.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Dec 20;266(2):405-10 [10600516.001]
  • [Cites] Development. 2000 Jun;127(12):2537-48 [10821753.001]
  • [Cites] Nature. 2000 Nov 2;408(6808):92-6 [11081514.001]
  • [Cites] Leukemia. 2001 Jan;15(1):89-94 [11243405.001]
  • [Cites] EMBO Rep. 2001 Feb;2(2):113-8 [11258702.001]
  • [Cites] EMBO J. 2001 Apr 17;20(8):1952-62 [11296228.001]
  • [Cites] Oncogene. 2001 Jan 18;20(3):404-9 [11313971.001]
  • [Cites] Ann N Y Acad Sci. 2001 Jun;938:96-107; discussion 108 [11458531.001]
  • [Cites] EMBO J. 2001 Dec 17;20(24):7184-96 [11742995.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2729-40 [11965546.001]
  • [Cites] Blood. 2002 Jul 15;100(2):458-66 [12091336.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):259-71 [12676584.001]
  • [Cites] Nucleic Acids Res. 2003 Jun 1;31(11):2735-44 [12771199.001]
  • [Cites] Development. 2003 Sep;130(17):4217-27 [12874139.001]
  • [Cites] Methods. 2003 Sep;31(1):24-32 [12893170.001]
  • [Cites] J Exp Med. 2004 Jan 5;199(1):5-14 [14707111.001]
  • [Cites] Blood. 2004 Feb 1;103(3):886-9 [14525762.001]
  • [Cites] Front Biosci. 2004 Jan 1;9:24-31 [14766340.001]
  • [Cites] Genet Res. 1981 Jun;37(3):303-9 [7262555.001]
  • [Cites] EMBO J. 1993 Jul;12(7):2715-21 [8334990.001]
  • [Cites] Cell. 1996 Jan 26;84(2):321-30 [8565077.001]
  • [Cites] Curr Opin Cell Biol. 1995 Dec;7(6):862-9 [8608017.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1059-64 [9353180.001]
  • (PMID = 19264921.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / C147/A6058
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / MOZ protein, mouse
  • [Other-IDs] NLM/ PMC2686138
  •  go-up   go-down


2. Kim KE, Kim SH, Han JY: [Acute Monocytic Leukemia with t(11;17)(q23;q21) Involving a Rearrangement of Mixed Lineage Leukemia Gene.]. Korean J Lab Med; 2006 Oct;26(5):329-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute Monocytic Leukemia with t(11;17)(q23;q21) Involving a Rearrangement of Mixed Lineage Leukemia Gene.].
  • A case of acute monocytic leukemia (AMoL) by French-American-British (FAB) classification in a 63-year-old male showed the abnormal karyotype 46,XY,t(11;17)(q23;q21), previously reported as a variant translocation in acute promyelocytic leukemia (APL).
  • Fluorescence in situ hybridization (FISH) analysis identified a mixed lineage leukemia (MLL) gene rearrangement, but not visible disruptions of promyelocytic leukemia (PML) or retinoic acid receptor alpha (RARA) genes.
  • Now, a few cases of AMoL with a similar translocation have been reported in the literature, and these cases emphasize the importance of cytogenetic and FISH studies in addition to morphology, cytochemistry, and immunophenotype in classifying acute myeloid leukemia (AML).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156746.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


3. Chan WK, Cheung CC, Law HK, Lau YL, Chan GC: Ganoderma lucidum polysaccharides can induce human monocytic leukemia cells into dendritic cells with immuno-stimulatory function. J Hematol Oncol; 2008;1:9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ganoderma lucidum polysaccharides can induce human monocytic leukemia cells into dendritic cells with immuno-stimulatory function.
  • The question of how leukemic cells especially in monocytic lineage respond to GL-PS stimuli remains unclear.
  • RESULTS: In this study, we used in vitro culture model with leukemic monocytic cell-lines THP-1 and U937 as monocytic effectors cells for proliferation responses and DCs induction.
  • CONCLUSION: Our findings suggested that GL-PS could induce selected monocytic leukemic cell differentiation into DCs with immuno-stimulatory function.
  • The possible clinical impact of using this commonly used medicinal mushroom in patients with monocytic leukemia (AML-M4 and M5) deserved further investigation.
  • [MeSH-major] Adjuvants, Immunologic / pharmacology. Dendritic Cells / immunology. Leukemia / immunology. Monocytes / immunology. Polysaccharides / immunology. Reishi / chemistry

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2000 Sep-Oct;22(5):412-6 [11037851.001]
  • [Cites] Leuk Res. 2006 Jul;30(7):841-8 [16423392.001]
  • [Cites] J Immunol. 2001 Nov 15;167(10):6021-30 [11698483.001]
  • [Cites] Blood. 2002 Jul 15;100(2):701-3 [12091369.001]
  • [Cites] Immunol Lett. 2002 Oct 1;83(3):163-9 [12095706.001]
  • [Cites] Pediatr Res. 2003 Jul;54(1):105-12 [12672905.001]
  • [Cites] J Altern Complement Med. 2003 Aug;9(4):491-7 [14499024.001]
  • [Cites] Oncol Rep. 2004 Sep;12(3):659-62 [15289852.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 8;323(1):133-41 [15351712.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1983 Spring;5(1):65-71 [6859456.001]
  • [Cites] Anticancer Res. 1992 Jul-Aug;12(4):1211-5 [1503411.001]
  • [Cites] Crit Rev Immunol. 1999;19(1):65-96 [9987601.001]
  • [Cites] Acta Pharmacol Sin. 2004 Nov;25(11):1387-95 [15525457.001]
  • [Cites] J Immunol. 2004 Nov 15;173(10):5989-99 [15528333.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 5;333(3):896-907 [15963458.001]
  • [Cites] J Leukoc Biol. 2005 Aug;78(2):533-43 [15894585.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):777-80 [16115136.001]
  • [Cites] J Altern Complement Med. 2005 Dec;11(6):1047-57 [16398597.001]
  • [Cites] Exp Mol Med. 2006 Feb 28;38(1):72-84 [16520555.001]
  • [Cites] J Altern Complement Med. 2001 Jun;7(3):281-7 [11439851.001]
  • (PMID = 18644156.001).
  • [ISSN] 1756-8722
  • [Journal-full-title] Journal of hematology & oncology
  • [ISO-abbreviation] J Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Polysaccharides; 130068-27-8 / Interleukin-10; 187348-17-0 / Interleukin-12; 207137-56-2 / Interleukin-4; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Other-IDs] NLM/ PMC2517069
  •  go-up   go-down


Advertisement
4. Xu N, Liu XL, DU QF, Liu Z, Zhong M, Lin R, Song LL, Yi ZS, Meng FY, Zhou SY: [CD56 and CD11b antigen expressions in patients with acute monocytic leukemia and the clinical implications]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Aug;29(8):1605-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CD56 and CD11b antigen expressions in patients with acute monocytic leukemia and the clinical implications].
  • OBJECTIVE: To investigate the expressions of cell surface differentiation antigen CD56 and CD11b antigen in acute monocytic leukemic (AML-M(5)) cells and their clinical significance.
  • Compared with the patients positive for both CD56 and CD11b, those negative for both CD56 and CD11b showed increased peripheral blood white blood cell (WBC) count and also increased blast and progenitor cells in the bone marrow (P<0.05); the former patients often had karyotypic abnormalities, commonly involving 11q23 aberrations (P<0.05), whereas the latter patients presented more likely with extramedullary infiltration and refractory leukemia (P<0.01) with lowered complete remission rate and shortened median survival time (P<0.01).
  • CD56-positive patients were more likely to have karyotypic abnormalities and refractory leukemia than CD11b-postive patients (P<0.05), but the peripheral blood WBC counts, bone marrow blast and progenitor cells, extramedullary infiltration, complete remission rate or median survival time showed no significant differences between them (P>0.05).
  • CONCLUSION: AML-M(5) patients with CD56 positivity and high expression of CD11b often have aberrant karyotypes, commonly involving 11q23/MLL gene abnormality.
  • These patients frequently develop extramedullary infiltration and refractory leukemia often with poor prognosis.
  • [MeSH-major] Antigens, CD11b / metabolism. Antigens, CD56 / metabolism. Gene Expression Regulation. Leukemia, Monocytic, Acute / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19726305.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD11b; 0 / Antigens, CD56
  •  go-up   go-down


5. Fatahzadeh M, Krakow AM: Manifestation of acute monocytic leukemia in the oral cavity: a case report. Spec Care Dentist; 2008 Sep-Oct;28(5):190-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Manifestation of acute monocytic leukemia in the oral cavity: a case report.
  • Within a week he developed signs and symptoms of systemic disease and upon further investigation, he was diagnosed with acute monocytic leukemia to which he succumbed within 72 hours.
  • The implications of gingival bleeding are discussed, and the necessity to consider systemic disease in the differential diagnosis is emphasized.
  • [MeSH-major] Gingival Hemorrhage / etiology. Leukemia, Monocytic, Acute / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18782195.001).
  • [ISSN] 0275-1879
  • [Journal-full-title] Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry
  • [ISO-abbreviation] Spec Care Dentist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Demirer S, Ozdemir H, Sencan M, Marakoglu I: Gingival hyperplasia as an early diagnostic oral manifestation in acute monocytic leukemia: a case report. Eur J Dent; 2007 Apr;1(2):111-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gingival hyperplasia as an early diagnostic oral manifestation in acute monocytic leukemia: a case report.
  • Acute Myeloblastic Leukemia (AML) is a malignant disease of bone marrow.
  • Due to its high morbidity rate, early diagnosis and appropriate medical therapy is essential.
  • A medical consultation was asked from hematology clinics and after a detailed medical examination Acute Monocytic Leukemia (FAB M5) was rendered.
  • Also, early medical therapy in acute monocytic leukemia may resolve the gingival hyperplasia that companies the disease progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aust Dent J. 1996 Aug;41(4):235-7 [8870276.001]
  • [Cites] J Nihon Univ Sch Dent. 1997 Jun;39(2):67-70 [9293702.001]
  • [Cites] J Am Dent Assoc. 1988 Dec;117(7):835-7 [3204244.001]
  • [Cites] J Periodontol. 1984 Oct;55(10):585-8 [6387081.001]
  • [Cites] J Am Dent Assoc. 1986 Dec;113(6):899-900 [3466936.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1986 May;61(5):466-70 [3459123.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1983 Jun;55(6):572-9 [6576290.001]
  • [Cites] Int J Oral Surg. 1978 Apr;7(2):119-22 [98458.001]
  • [Cites] J Periodontol. 2002 Jun;73(6):664-8 [12083541.001]
  • [Cites] J Periodontol. 2000 May;71(5 Suppl):876-9 [10875698.001]
  • [Cites] Ann Periodontol. 1999 Dec;4(1):54-64 [10863375.001]
  • [Cites] Mt Sinai J Med. 1998 Oct-Nov;65(5-6):309-15 [9844357.001]
  • [Cites] J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):491-9 [15761428.001]
  • [Cites] J Can Dent Assoc. 2000 Feb;66(2):78-9 [10730004.001]
  • [Cites] J Periodontol. 1988 Dec;59(12):852-5 [3225733.001]
  • (PMID = 19212486.001).
  • [ISSN] 1305-7456
  • [Journal-full-title] European journal of dentistry
  • [ISO-abbreviation] Eur J Dent
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Other-IDs] NLM/ PMC2609944
  • [Keywords] NOTNLM ; Acute monocytic leukemia / Gingival hyperplasia
  •  go-up   go-down


7. Ji YY, Zhang WG, Chen YX, Zhao XM, He AL, Liu J, Wang JL, Wang FX, Zhang PY, Zhang WJ: [Efficiency of GHA priming therapy on patients with acute monocytic leukemia and its mechanism]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb;18(1):213-8
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficiency of GHA priming therapy on patients with acute monocytic leukemia and its mechanism].
  • The aim of this study was to explore the clinical efficiency and side effects of GHA-priming therapy on patients with acute monocytic leukemia, and to analyze its mechanism.
  • 37 patients with refractory, relapse, hypocellular acute monocytic leukemia and elderly patients with AML-M(5) were treated with GHA-priming therapy (G-CSF, homoharringtonine and low dosage of cytarabine).
  • Other non-hematological toxicities were low in vitro when incubated with G-CSF for 24 hours, the S-phase cells obviously increased.
  • It is concluded that the GHA priming therapy can be used to treat patients with refractory, relapse, senile and hypocellular acute monocytic leukemia with satisfied response rate and low hematological and non-hematological toxicities.
  • MLAA-34 is a novel anti-apoptotic factor of acute monocytic leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137150.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Harringtonines; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6FG8041S5B / homoharringtonine
  •  go-up   go-down


8. Rokudai S, Aikawa Y, Tagata Y, Tsuchida N, Taya Y, Kitabayashi I: Monocytic leukemia zinc finger (MOZ) interacts with p53 to induce p21 expression and cell-cycle arrest. J Biol Chem; 2009 Jan 2;284(1):237-44
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monocytic leukemia zinc finger (MOZ) interacts with p53 to induce p21 expression and cell-cycle arrest.
  • Here we show that monocytic leukemia zinc finger (MOZ) forms a complex with p53 to induce p21 expression and cell-cycle arrest.
  • The leukemia-associated MOZ-CBP fusion protein inhibits p53-mediated transcription.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19001415.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cdkn1a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Recombinant Fusion Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / KAT6A protein, human; EC 2.3.1.48 / MOZ protein, mouse
  •  go-up   go-down


9. Zhang GS, Dai CW, Peng HL, Xu YX, Pei MF: Myelodysplastic syndrome with transformation to acute monocytic leukemia with FLT3-ITD mutation following orthotopic liver transplantation. Leuk Res; 2006 Jul;30(7):908-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelodysplastic syndrome with transformation to acute monocytic leukemia with FLT3-ITD mutation following orthotopic liver transplantation.
  • A rare case of a 46-year-old man who underwent myelodysplastic syndrome, acute monocytic leukemia with FLT3-ITD mutation and splenic disruption following orthotopic liver transplantation is reported.
  • The study of this case may be helpful to understand both the pathogenesis of acute leukemia and new complication of liver transplantation.
  • [MeSH-major] Gene Duplication. Leukemia, Monocytic, Acute / etiology. Leukemia, Monocytic, Acute / therapy. Liver Transplantation / adverse effects. Myelodysplastic Syndromes / complications. Myelodysplastic Syndromes / therapy. fms-Like Tyrosine Kinase 3 / genetics


10. Tian L, Liu LB, Wang XB, Xiao J, Zou P: Impact of trisomy 8 on cytobiological and clinical features of acute myelomonocytic and monocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun;13(3):364-8
Genetic Alliance. consumer health - Acute Myelomonocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of trisomy 8 on cytobiological and clinical features of acute myelomonocytic and monocytic leukemia.
  • To evaluate the impact of trisomy 8 on cytobiological and clinical features of acute myelomonocytic and monocytic leukemia (M(4), M(5)), a total of 56 cases of acute myelomonocytic and monocytic leukemia were investigated.
  • It is concluded that trisomy 8 may play an important role in the pathogenesis and progression of acute myelomonocytic/monocytic leukemia (M(4)/M(5)), whic seems to be related with a block in differentiation of monocytes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15972121.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / HLA-DR Antigens; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


11. Shadat NM, Koide N, Khuda II, Dagvadorj J, Tumurkhuu G, Naiki Y, Komatsu T, Yoshida T, Yokochi T: Retinoblastoma protein-interacting zinc finger 1 (RIZ1) regulates the proliferation of monocytic leukemia cells via activation of p53. Cancer Invest; 2010 Oct;28(8):806-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinoblastoma protein-interacting zinc finger 1 (RIZ1) regulates the proliferation of monocytic leukemia cells via activation of p53.
  • The role of retinoblastoma protein-interacting zinc finger 1 (RIZ1) on the cell growth of mouse and human monocytic leukemia cells was examined.
  • Therefore, it is suggested that RIZ1 negatively regulated the cell proliferation of monocytic leukemia cells via activation of p53.
  • [MeSH-major] DNA-Binding Proteins / pharmacology. Histone-Lysine N-Methyltransferase / pharmacology. Leukemia, Myeloid / pathology. Nuclear Proteins / pharmacology. Transcription Factors / pharmacology. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Retinoblastoma.
  • National BioResource Project. culture/stock collections - NBRP resources .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20594067.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / Tumor Necrosis Factor-alpha; 0 / Tumor Suppressor Protein p53; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.1.1.43 / PRDM2 protein, human
  •  go-up   go-down


12. Ru YX, Mi YC, Liu JH, Wang HJ, Zhao SX, Cui W, Li CW, Li QH, Zhu XF, Xiao ZJ, Pang JX, Wang JX: Significance of transmission electron microscopy in subtyping of monocytic leukemia. Ultrastruct Pathol; 2009 Mar-Apr;33(2):67-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of transmission electron microscopy in subtyping of monocytic leukemia.
  • The objective of this paper is to produce an ultrastructural classification of acute monocytic leukemia (AML-M5) in relation to clinical behaviors.
  • The ultrastructural characteristics of blasts of the monocytic series were analyzed in 72 M5 patients by transmission electron microscopy (TEM), in terms of their content of typical monoblasts, atypical monoblasts, atypical promonocytes, and typical promonocytes in bone-marrow aspirates.
  • Four kinds of monocytic blasts were identified by cell size and shape, nuclear profile, nucleocytoplasmic ratio, heterochromatin content, nucleolus, granules, vesicles, and Golgi apparatus.
  • Monoblast-type patients expressed weaker monocytic enzymograms and specific antigen staining for CD14 and CD64, compared with promonocyte-type patients.
  • [MeSH-major] Immunophenotyping / methods. Leukemia, Monocytic, Acute / classification. Microscopy, Electron, Transmission / methods. Monocyte-Macrophage Precursor Cells / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19274583.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


13. Taki T, Akiyama M, Saito S, Ono R, Taniwaki M, Kato Y, Yuza Y, Eto Y, Hayashi Y: The MYO1F, unconventional myosin type 1F, gene is fused to MLL in infant acute monocytic leukemia with a complex translocation involving chromosomes 7, 11, 19 and 22. Oncogene; 2005 Aug 4;24(33):5191-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The MYO1F, unconventional myosin type 1F, gene is fused to MLL in infant acute monocytic leukemia with a complex translocation involving chromosomes 7, 11, 19 and 22.
  • We analysed a complex translocation involving chromosomes 7, 11, 19 and 22 in infant acute monocytic leukemia, and identified that the MLL gene on 11q23 was fused to the unconventional myosin type 1F, MYO1F, gene on 19p13.2-13.3.
  • Further analysis of this novel type of MLL fusion protein would provide new insights into leukemogenesis.
  • [MeSH-major] DNA-Binding Proteins / genetics. Leukemia, Monocytic, Acute / genetics. Myosin Type I / genetics. Proto-Oncogenes / genetics. Transcription Factors / genetics. Translocation, Genetic
  • [MeSH-minor] Amino Acid Sequence. Base Sequence. Cell Line, Tumor. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 19. Chromosomes, Human, Pair 22. Chromosomes, Human, Pair 7. Female. Gene Rearrangement. Histone-Lysine N-Methyltransferase. Humans. Infant. Molecular Sequence Data. Myeloid-Lymphoid Leukemia Protein

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15897884.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 3.6.1.- / Myosin Type I
  •  go-up   go-down


14. Sindt A, Deau B, Brahim W, Staal A, Visanica S, Villarese P, Rault JP, Macintyre E, Delabesse E: Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9. Genes Chromosomes Cancer; 2006 Jun;45(6):575-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9.
  • The t(9;22)(q34;q11) translocation occurs in chronic myeloid leukemia (CML) and adult B-cell acute lymphoblastic leukemia (ALL), leading to fusion of BCR to ABL1 and constitutive activation of ABL1 tyrosine kinase activity.
  • We describe here the first case of t(9;22)(q34;q11) associated with t(10;11)(p13;q14) in acute monocytic leukemia.
  • The recurrent t(10;11)(p13;q14) translocation, usually found in acute myeloid leukemia (AML) and T-ALL, merges PICALM to MLLT10.
  • RT-PCR enabled identification of PICALM-MLLT10 and BCR-ABL1 e1-a2 fusion transcripts; in the context of chronic and acute myeloid leukemia, the latter usually has a monocytic presentation.
  • We also identified overexpression of HOXA9, a gene essential to myeloid differentiation that is expressed in PICALM-MLLT10 and MLL-rearranged acute leukemias.
  • [MeSH-major] Fusion Proteins, bcr-abl / metabolism. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / metabolism. Leukemia, Monocytic, Acute / genetics. Oncogene Proteins, Fusion / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16518848.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / MLLT10 protein, human; 0 / Monomeric Clathrin Assembly Proteins; 0 / Oncogene Proteins, Fusion; 0 / PICALM protein, human; 0 / PICALM-MLLT10 fusion protein, human; 0 / Transcription Factors; 0 / homeobox protein HOXA9; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


15. Tong W, Stevenson W, Cortes J, Needham L, Brotherton D, Davidson A, Drummond A, Garcia-Manero G: In vitro and in vivo anti-leukemia activity of CHR-2845, a cell-targeted HDAC inhibitor for use in monocytic leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):e14579

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro and in vivo anti-leukemia activity of CHR-2845, a cell-targeted HDAC inhibitor for use in monocytic leukemia.
  • : e14579 Background: Histone deacetylase inhibitors alter gene expression and induce apoptosis in a wide range of cancer cells including those derived from human leukemias.
  • METHODS: We studied the in vitro and in vivo anti-leukemia activity of CHR-2845 using cell proliferation assay, annexin V binding assay, cell cycle analysis, western blot and in vitro primary leukemia cell culture.
  • In comparison to vorinostat, CHR-2845 showed increased anti-proliferative potency (IC<sub>50</sub>) against monocytic cell lines (THP1, 30 nM vs 700 nM and U937, 30 nM vs 475 nM), compared to a myeloid cell line (HL60, 700nM vs 470 nM).
  • In monocytic cell lines, CHR-2845 induced more apoptosis than vorinostat (THP1: 45±5% vs 11±1% and U937: 23±14% vs 6±1%), as measured by flow cytometry using Annexin V.
  • Biochemical assessment of histone H3 and H4 protein acetylation by Western blot also indicateed that CHR-2845 is at least 10 times more potent than vorinostat in monocytic cell lines but not in HL-60 cells.
  • These data for CHR-2845 and vorinostat on apoptosis and histone acetylation in THP1 and U937 versus HL60 cells, confirmed the selectivity of this novel compound for cells of the monocytic lineage.
  • We also studied the anti-leukemia activity of CHR-2845 in primary leukemia cells from 8 patients with acute or chronic myelomonocytic leukemia.
  • CONCLUSIONS: These results indicated that CHR-2845 has potential to be efficacious in the treatment of patients with monocytic leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963654.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Li Z, Chen Z, Lu J, Cen J, He J, Chen S, Xue Y, Guo L: Establishment of a nude mice model of human monocytic leukemia with CNS and multiorgan extramedullary infiltration. Eur J Haematol; 2006 Aug;77(2):128-33
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of a nude mice model of human monocytic leukemia with CNS and multiorgan extramedullary infiltration.
  • OBJECT: To establish a human monocytic leukemia model with central nervous system infiltration in BALB/c nude mice.
  • METHODS: BALB/c nu/nu mice, pretreated by splenectomy, cytoxan intraperitoneal injection, and sublethal irradiation, were transplanted intravenously with human monocytic leukemic cell line SHI-1.
  • CONCLUSIONS: SHI-1 cells could engraft in the SCI-nu/nu mice, creating an efficient and reproducible experimental model of central nervous system leukemia (CNSL) and multiorgan infiltration.
  • [MeSH-major] Leukemia, Myeloid / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16856908.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


17. Scrideli CA, Baruffi MR, Squire JA, Ramos ES, Karaskova J, Heck B, Tone LG: Acute monocytic leukemia and multiple abnormalities in a child with duplication of 1q detected by GTG-banding and SKY. Leuk Res; 2005 Dec;29(12):1465-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute monocytic leukemia and multiple abnormalities in a child with duplication of 1q detected by GTG-banding and SKY.
  • We describe a case of partial trisomy 1q "syndrome" and acute monocytic leukemia.
  • [MeSH-major] Abnormalities, Multiple / genetics. Chromosomes, Human, Pair 1. Leukemia, Monocytic, Acute / genetics. Trisomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15964069.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


18. Liu LB, Li L, Zou P: Comparison of cytogenetics and clinical manifestations between M5a and M5b of acute monocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug;14(4):654-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of cytogenetics and clinical manifestations between M5a and M5b of acute monocytic leukemia.
  • To compare the cytogenetic difference between M5a and M5b of acute monocytic leukemia and to study the correlation between karyotypes and clinical manifestations, a total of 58 cases of de novo adult AML M5 have been investigated.
  • It is concluded that acute monocytic leukemia is a series of heterogeneous diseases, a distinctive cytogenetic features can be observed between patients with AML M5a and M5b, these results will provide insights into the classification and pathogenesis mechanism of AML M5 at molecular level.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928293.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Imagama S, Abe A, Suzuki M, Hayakawa F, Katsumi A, Emi N, Kiyoi H, Naoe T: LRP16 is fused to RUNX1 in monocytic leukemia cell line with t(11;21)(q13;q22). Eur J Haematol; 2007 Jul;79(1):25-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LRP16 is fused to RUNX1 in monocytic leukemia cell line with t(11;21)(q13;q22).
  • OBJECTIVE: The RUNX1 (also known as AML1) gene is observed frequently as the target of chromosomal rearrangements in human acute leukemia.
  • We describe here a previously unreported rearrangement, t(11;21)(q13;q22), that disrupts the RUNX1 gene in a patient with acute leukemia and the molecular analysis of the fusion gene.
  • METHODS: We have established a monocytic leukemia cell line, ELAM-1, from a patient with acute leukemia evolving from myelodysplastic syndrome (MDS).
  • Translocation (11;21) (q13;q22) was observed in both patient leukemia cells and ELAM-1.
  • Although it was reported that overexpression of LRP16 promotes human breast cancer cell proliferation, the function of LRP16 in leukemia remains to be studied.
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 21. Core Binding Factor Alpha 2 Subunit / genetics. Leukemia, Monocytic, Acute / genetics. Neoplasm Proteins / genetics. Translocation, Genetic

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17532767.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / DNA Primers; 0 / LRP16 protein, human; 0 / Neoplasm Proteins; 0 / RUNX1 protein, human
  •  go-up   go-down


20. Sun Y, Kong F, Ren S, Yuan F, Liang F, Liu N, Jin L, Xi Y: Severe acute graft-vs-host disease in a patient with acute monocytic leukemia having a recombination event between HLA-A/B loci from a multiple recombinant family. Tissue Antigens; 2007 Dec;70(6):499-505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe acute graft-vs-host disease in a patient with acute monocytic leukemia having a recombination event between HLA-A/B loci from a multiple recombinant family.
  • Here, we report for the first time that a 30-year-old female acute monocytic leukemia patient with an HLA-A/B recombinant haplotype, who has three unmatched and one HLA-B/DRB1 recombinant haplotype siblings, presented grade IV acute GVHD (aGVHD) after transplantation from a sibling with a single allele only mismatch at the classical HLA-A locus.
  • [MeSH-major] Graft vs Host Disease / genetics. HLA-A Antigens / genetics. HLA-B Antigens / genetics. Leukemia, Monocytic, Acute / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17990988.001).
  • [ISSN] 0001-2815
  • [Journal-full-title] Tissue antigens
  • [ISO-abbreviation] Tissue Antigens
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / HLA-A Antigens; 0 / HLA-B Antigens
  •  go-up   go-down


21. Chen YX, Wang WP, Zhang PY, Zhang WG, Liu J, Ma XR: [Expression of genes psma6 and slc25a4 in patients with acute monocytic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct;17(5):1168-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of genes psma6 and slc25a4 in patients with acute monocytic leukemia].
  • The aim of this study was to investigate the expression levels of genes psma6 and slc25a4 in bone marrow of patients with acute monocytic leukemia and their correlation with clinical features and prognosis.
  • The expression levels of genes psma6 and slc25a4 in AML-M5 leukemia cells, normal blood cells and non-leukemia cells were detected by real-time quantitative RT-PCR and compared each other.
  • The results showed that the expression levels of psma6 mRNA in AML-M5 leukemia cells was lower than that in non AML-M5 leukemia cells, non-leukemia cells and normal blood cells.
  • It is concluded that the expression level of psma6 is probably a new prognostic indicator of acute monocytic leukemia, slc25a4 may be a novel gene of antigen associated with acute monocytic leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19840444.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adenine Nucleotide Translocator 1; EC 3.4.25.1 / PSMA6 protein, human; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


22. Zhang PY, Zhang WG, He AL, Wang JL, Li WB: Identification and functional characterization of the novel acute monocytic leukemia associated antigen MLAA-34. Cancer Immunol Immunother; 2009 Feb;58(2):281-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and functional characterization of the novel acute monocytic leukemia associated antigen MLAA-34.
  • We have previously applied the method of serologic analysis of recombinant cDNA expression library (SEREX) on acute monocytic leukemia to identify monocytic leukemia-associated antigens.
  • Using this approach, we identified a novel gene, MLAA-34, which exclusively reacted with sera from allogeneic leukemia patients but not with normal donor sera.
  • Thus, we propose that MLAA-34 is a novel CAB39L's splice variant associated with acute monocytic leukemia.
  • The results showed that the downregulation of MLAA-34 expression significantly suppressed the proliferation of U937 cells in vitro, and increased the spontaneous apoptosis of these leukemia cells.
  • All these data indicated that MLAA-34 may be a novel anti-apoptotic factor related closely to carcinogenesis or progression of acute monocytic leukemia.
  • This study warrants further investigations to verify MLAA-34 as a promising antigen and a molecular target for therapeutic applications in acute monocytic leukemia.
  • [MeSH-major] Antigens, Neoplasm / genetics. Apoptosis Regulatory Proteins / genetics. Leukemia, Monocytic, Acute / genetics. Leukemia, Monocytic, Acute / immunology. Monocytes / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592235.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Apoptosis Regulatory Proteins; 0 / CAB39L protein, human
  •  go-up   go-down


23. Martínez-Poventud G, Fradera J, Pérez S, Fernández A, Pacheco E, Acabá L, López-Enriquez A, Román-Díaz A, Castro-Montalvo J, Vélez-García E: Aleukemic leukemia cutis preceding acute monocytic leukemia: a case report. P R Health Sci J; 2008 Sep;27(3):256-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aleukemic leukemia cutis preceding acute monocytic leukemia: a case report.
  • Aleukemic leukemia cutis is an extremely rare clinical presentation in patients who eventually develop acute leukemia, usually of monocytic lineage.
  • We report a case of a 33 years old female with leukemia cutis preceding the onset of acute monocytic leukemia by four months.
  • To our knowledge, this is the first documented case in Puerto Rico with the diagnosis of leukemia cutis preceding acute monocytic leukemia.
  • [MeSH-major] Leukemia, Monocytic, Acute / pathology. Leukemic Infiltration. Skin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18782972.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


24. Liu LB, Li L, Xiao J, Zou P: Comparison of immunophenotype and clinical manifestations between patients with M5a and M5b of acute monocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec;14(6):1079-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of immunophenotype and clinical manifestations between patients with M5a and M5b of acute monocytic leukemia.
  • Acute monocytic leukemia is a distinct subtype of acute myeloid leukemia (AML) with characteristic biology and clinical features.
  • The results showed that the immunophenotypes of monocytic leukemic cells in patients with AML M(5) were heterogeneous, and CD68 and CD11b were expressed higher in patients with AML M(5a), compared with that in patients with AML M(5b) (P < 0.01).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204168.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD11b; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human
  •  go-up   go-down


25. Li ZJ, Chen ZX, Cen JN, Lu J, He J: [Establishment of a nude mouse model of human monocytic leukemia with multi-organ infiltration]. Ai Zheng; 2006 Oct;25(10):1307-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Establishment of a nude mouse model of human monocytic leukemia with multi-organ infiltration].
  • BACKGROUND & OBJECTIVE: Acute leukemia is always accompanied by extramedullary infiltration, which may be the source of relapse.
  • METHODS: After being treated by splenectomy, cytoxan intraperitoneal injection, and sublethal irradiation, 4-and 6-week old BALB/c nu/nu mice were transplanted intravenously with 5x10(6) or 1x10(7) of SHI-1 human monocytic leukemic cells.
  • [MeSH-major] Disease Models, Animal. Leukemia, Monocytic, Acute / pathology. Leukemic Infiltration / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059783.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


26. Hijiya N, Metzger ML, Pounds S, Schmidt JE, Razzouk BI, Rubnitz JE, Howard SC, Nunez CA, Pui CH, Ribeiro RC: Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia. Pediatr Blood Cancer; 2005 Jan;44(1):63-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia.
  • BACKGROUND: Life-threatening pulmonary complications that coincide with cell lysis during early chemotherapy and that mimic systemic inflammatory response syndrome (SIRS) have been reported in patients with acute myeloid leukemia (AML).
  • Severe SIRS was significantly more common in myelomonocytic or monocytic AML (M4/M4eo/M5) than in other subtypes (P = 0.010) and significantly more common in M4eo than in M4/M5 (P = 0.008).
  • [MeSH-major] Cell Death. Leukemia, Monocytic, Acute / complications. Leukemia, Monocytic, Acute / drug therapy. Leukemia, Myelomonocytic, Acute / complications. Leukemia, Myelomonocytic, Acute / drug therapy. Systemic Inflammatory Response Syndrome / etiology

  • Genetic Alliance. consumer health - Acute Myelomonocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15368547.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


27. Yamamoto K, Okamura A, Wakahashi K, Katayama Y, Shimoyama M, Matsui T: A novel unbalanced whole-arm translocation der(3;10)(q10;q10) in acute monocytic leukemia. Cancer Genet Cytogenet; 2010 Jun;199(2):134-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel unbalanced whole-arm translocation der(3;10)(q10;q10) in acute monocytic leukemia.
  • We describe here a novel unbalanced whole-arm translocation der(3;10)(q10;q10) in a 58-year-old man with acute monocytic leukemia.
  • These monocytic cells were positive for myeloperoxidase and alpha-naphthyl butyrate esterase staining.
  • Spectral karyotyping confirmed der(3;10)(q10;q10) as a sole structural abnormality.
  • The +3,der(3;10)(q10;q10) is thought to play a crucial role in the pathogenesis of acute monocytic leukemia because of the gain of 3q or the loss of 10p.
  • [MeSH-major] Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 3 / genetics. Leukemia, Monocytic, Acute / genetics. Translocation, Genetic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20471517.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Imataki O, Ohnishi H, Yamaoka G, Arai T, Kitanaka A, Kubota Y, Kushida Y, Ishida T, Tanaka T: Lineage switch from precursor B cell acute lymphoblastic leukemia to acute monocytic leukemia at relapse. Int J Clin Oncol; 2010 Feb;15(1):112-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lineage switch from precursor B cell acute lymphoblastic leukemia to acute monocytic leukemia at relapse.
  • A lineage switch in leukemia, in which the leukemic cell lineage at onset converts to another lineage at a later time, is an uncommon type of hybrid (mixed) leukemia regarded as a variation of bilineage leukemia.
  • We present a case of a 60-year-old female diagnosed with precursor B cell acute lymphoblastic leukemia (ALL), whose markers in flow cytometry shifted from their original status of CD19+, 22+, 79a+, 13+, HLA-DR+, and TdT+.
  • Two weeks after liver biopsy, blast cells progressively appeared in the peripheral blood; these cells had a monocytoid morphology and phenotype (CD13, 14) but were accompanied by myeloid (CD33) and lymphoid (CD2, 4, 20) cells.
  • This phenotypical conversion from B-ALL to hybrid leukemia featuring monocytoid characteristics is known as a lineage switch.
  • [MeSH-major] Leukemia, Biphenotypic, Acute / pathology. Leukemia, Monocytic, Acute / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1995 Dec;9(12):2023-6 [8609712.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):311-21 [15803157.001]
  • [Cites] Br J Haematol. 1987 Mar;65(3):261-4 [3552021.001]
  • [Cites] Leuk Lymphoma. 2005 Aug;46(8):1223-7 [16085566.001]
  • [Cites] Blood. 1984 Sep;64(3):701-6 [6590097.001]
  • [Cites] Blood. 1989 Nov 1;74(6):2088-95 [2553159.001]
  • [Cites] Haematologica. 2004 Aug;89(8):ECR28 [15339697.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jan 15;164(2):118-21 [16434313.001]
  • [Cites] Am J Hematol. 2000 Sep;65(1):72-4 [10936868.001]
  • [Cites] Clin Haematol. 1986 Aug;15(3):811-27 [3536242.001]
  • [Cites] Blood Rev. 1988 Mar;2(1):9-15 [3289656.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jul 15;168(2):146-9 [16843104.001]
  • [Cites] Br J Haematol. 1993 May;84(1):49-60 [7687860.001]
  • (PMID = 20066454.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


29. Yamamoto K, Okamura A, Kawano H, Katayama Y, Shimoyama M, Matsui T: A novel t(8;18)(q13;q21) in acute monocytic leukemia evolving from constitutional trisomy 8 mosaicism. Cancer Genet Cytogenet; 2007 Jul 15;176(2):144-9
Genetic Alliance. consumer health - Trisomy 18.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel t(8;18)(q13;q21) in acute monocytic leukemia evolving from constitutional trisomy 8 mosaicism.
  • We describe the case of a 38-year-old woman with a normal phenotype who developed to acute monocytic leukemia with a novel t(8;18)(q13;q21).
  • FISH also revealed that trisomy 8 was detected in buccal mucosa cells, indicating that trisomy 8 was a constitutional abnormality.
  • These results suggest that t(8;18)(q13;q21) had a crucial role in the development of leukemia as the second mutation following CT8M.
  • [MeSH-major] Chromosomes, Human, Pair 18. Chromosomes, Human, Pair 8. Leukemia, Monocytic, Acute / genetics. Mosaicism. Translocation, Genetic. Trisomy / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17656258.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


30. Li ZJ, Chen ZX, Lu J, Cen JN, He J, Guo LC: [Growth and infiltration of human monocytic leukemia cell in nude mice: a model for central nervous system leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2006 Jun;27(6):374-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Growth and infiltration of human monocytic leukemia cell in nude mice: a model for central nervous system leukemia].
  • OBJECTIVE: To establish a model of human monocytic leukemia with CNS infiltration in BALB/c nude mice.
  • METHODS: BALB/c nu/nu mice pre-treated by splenectomy, cytoxan intraperitoneal injection, and sublethal irradiation (SCI), were transplanted intravenously with 1 x 10(7) of human monocytic leukemic SHI-1 cells.
  • In brain leukemia cells were filled in the subdural space and pia-arachnoid, covered the surface of cerebrum, cerebellum, spread along the virchow-robin space on the surface of pia mater, and eventually invaded the brain parenchyma.
  • CONCLUSION: SHI-1 cells could engrafted in the SCI-nu/nu mice, form an efficient and reproducible experimental model of CNSL and systematic leukemia.
  • [MeSH-major] Central Nervous System Neoplasms. Leukemia, Experimental. Leukemia, Monocytic, Acute

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17147225.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


31. Suzukawa K, Shimizu S, Nemoto N, Takei N, Taki T, Nagasawa T: Identification of a chromosomal breakpoint and detection of a novel form of an MLL-AF17 fusion transcript in acute monocytic leukemia with t(11;17)(q23;q21). Int J Hematol; 2005 Jul;82(1):38-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a chromosomal breakpoint and detection of a novel form of an MLL-AF17 fusion transcript in acute monocytic leukemia with t(11;17)(q23;q21).
  • More than 40 genes have been reported as translocation partners of the mixed lineage leukemia gene (MLL) in hematologic malignancies.
  • On the other hand, there is only 1 report of an MLL-AF17 fusion transcript in acute myeloid leukemia (AML).
  • Here we describe a 40-year-old man with a diagnosis of AML involving t(11;17)(q23;q21).
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 17. DNA-Binding Proteins / genetics. Leukemia, Monocytic, Acute / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2003 Aug;4(2):99-110 [12957285.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14 ):4075-80 [12124344.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):333-7 [11809673.001]
  • [Cites] Nucleic Acids Res. 1988 Jun 24;16(12):5533-56 [2838820.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Aug;145(1):54-9 [12885463.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4261-5 [10485469.001]
  • [Cites] Oncogene. 2003 Jan 9;22(1):157-60 [12527918.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8107-11 [8058765.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):197-207 [14522254.001]
  • [Cites] Leukemia. 2002 Oct;16(10):1927-32 [12357344.001]
  • [Cites] Cancer Genet Cytogenet. 1994 May;74(1):50-3 [8194047.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5695-707 [11607819.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9597-602 [10920186.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 15;148(2):178-9 [14734237.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):33-7 [11782354.001]
  • (PMID = 16105757.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / MLL-AF17 fusion protein, human; 0 / MLLT6 protein, human; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


32. Sheng LX, Xie XB, Qiu GQ, Gu WY, Wang ZL, Wu HQ: [In vitro stimulation of specific antileukemia T-cell response by dendritic cells derived from CD14+ acute monocytic leukemia cells]. Ai Zheng; 2005 Nov;24(11):1338-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [In vitro stimulation of specific antileukemia T-cell response by dendritic cells derived from CD14+ acute monocytic leukemia cells].
  • BACKGROUND & OBJECTIVE: Dendritic cells (DCs) or DC-like cells had been successfully induced in vitro from leukemia cells, which may provide a promising immunotherapeutic protocol for leukemia.
  • This study was designed to investigate the efficiency of in vitro generation of dendritic cells from CD14+ acute myelomonocytic (M4) or monocytic (M5) leukemia cells and their ability of stimulating specific antileukemia T-cell response.
  • METHODS: Bone marrow mononuclear cells (BMMNCs) were isolated from 5 M4/M5 leukemia patients with high CD14 expression, and then divided into 3 groups: adherent leukemia cells, nonadherent blasts, and total unfractioned blasts.
  • When cultured with or without granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4) and tumor necrosis factor alpha (TNF-alpha) for 7-10 days, monocytic leukemia cell-derived dendritic cells (Mo-LDCs) were identified through morphologic observation and immunophenotype analysis using FCM.
  • RESULTS: The amount of CD14+ cells, which could differentiate into CD83+ mature DCs under induction of the cytokine combination, was higher in adherent leukemia cells than in nonadherent blasts and total unfractioned blasts.
  • Mo-LDCs exhibited typical morphology and phenotype as mature DCs, induced potent proliferation of homogeneous T cells in Allo-MLR, stimulated the expansion of leukemia-specific CTLs, and continued to possess the cytogenetic abnormalities of the original leukemia, as well as the aberrant expression of myeloid antigens.
  • CD14 expression level may predict the DCs differentiation ability of monocytic leukemia.
  • [MeSH-major] Antigens, CD14 / analysis. Dendritic Cells / immunology. Leukemia, Monocytic, Acute / pathology. T-Lymphocytes, Cytotoxic / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16552959.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD14; 0 / CD83 antigen; 0 / Immunoglobulins; 0 / Membrane Glycoproteins
  •  go-up   go-down


33. Chen G, Zhang W, Cao X, Li F, Liu X, Yao L: Serological identification of immunogenic antigens in acute monocytic leukemia. Leuk Res; 2005 May;29(5):503-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serological identification of immunogenic antigens in acute monocytic leukemia.
  • In order to improve disease-free survival and potentially a cure, it is necessary to identify more potent leukemia antigen.
  • Here, we defined the acute monocytic leukemia-associated antigen (LAA) recognized by the humoral immune system for the first time.
  • We have applied the method of serologic analysis of recombinant cDNA expression library (SEREX) on acute monocytic leukemia (FAB M5), followed by DNA sequencing and analyzing of positive clones.
  • Then, the reactivity of normal and other leukemia sera with positive clones were performed.
  • Thirty-five distinct novel antigens reactive with autologous IgG were identified by SEREX analysis on an acute monocytic leukemia patient and were characterized according to cDNA sequence and the reactivity with allogeneic sera.
  • Twenty of the 35 antigens identified in this study were recognized by IgG antibodies in normal sera, and the remaining 15 were recognized exclusively by sera from allogeneic leukemia patients but not by normal donor sera, suggested that the immune response to these 15 antigens are leukemia related.
  • The 15 immunogenic antigens detected by immune responses in the autologous host facilitate the identification of epitopes recognized by antigen-specific cytotoxic T lymphocytes (CTL) and are potential candidates for diagnosis and immunotherapy in acute myeloid leukemia (AML).
  • [MeSH-major] Antibodies, Neoplasm / immunology. Antigens, Neoplasm / immunology. Immunoglobulin G / immunology. Leukemia, Monocytic, Acute / immunology. T-Lymphocytes, Cytotoxic / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755502.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Immunoglobulin G
  •  go-up   go-down


34. Morerio C, Rapella A, Tassano E, Rosanda C, Panarello C: MLL-MLLT10 fusion gene in pediatric acute megakaryoblastic leukemia. Leuk Res; 2005 Oct;29(10):1223-6
Genetic Alliance. consumer health - Acute Megakaryoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MLL-MLLT10 fusion gene in pediatric acute megakaryoblastic leukemia.
  • The occurrence of MLL gene rearrangement in acute megakaryoblastic leukemia (AML-M7, acute myeloid leukemia, French-American-British type M7) is very rare and limited to pediatric age: in particular, MLL-MLLT10 fusion, previously reported as characteristic of monocytic leukemia, has been reported in only one case of pediatric megakaryoblastic leukemia.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Leukemia, Megakaryoblastic, Acute / genetics. Oncogene Proteins, Fusion / genetics
  • [MeSH-minor] Child, Preschool. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Myeloid-Lymphoid Leukemia Protein. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16111539.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MLL-AF10 fusion protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  • [Number-of-references] 15
  •  go-up   go-down


35. Al-Tawfiq JA, Al-Khatti AA: Spontaneous remission of acute monocytic leukemia after infection with Clostridium septicum. Int J Lab Hematol; 2007 Oct;29(5):386-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of acute monocytic leukemia after infection with Clostridium septicum.
  • Spontaneous remissions of acute myeloid leukemia (AML) have been reported in association with infection.
  • He was diagnosed with acute monocytic leukemia (AML, FAB M5b) and a perforated bowel.
  • [MeSH-major] Clostridium Infections / complications. Clostridium septicum / pathogenicity. Intestinal Perforation / complications. Leukemia, Monocytic, Acute / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17824921.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


36. Liu JJ, Zhang Y, Guang WB, Yang HZ, Lin DJ, Xiao RZ: Ponicidin inhibits monocytic leukemia cell growth by induction of apoptosis. Int J Mol Sci; 2008 Nov;9(11):2265-77

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ponicidin inhibits monocytic leukemia cell growth by induction of apoptosis.
  • In this study two monocytic leukemia cell lines, U937 and THP-1 cells, were used to investigate the anti-proliferation effects caused by ponicidin.
  • We therefore conclude that ponicidin has significant anti-proliferation effects by inducing apoptosis on leukemia cells in vitro, downregulation of survivin as well as Bcl-2 expressions may be the important apoptosis inducing mechanisms.
  • The results suggest that ponicidin may serve as potential therapeutic agent for leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 2007 Nov;31(11):1495-501 [17328950.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):127-34 [10656440.001]
  • [Cites] Int J Hematol. 2004 Oct;80(3):232-8 [15540897.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5071-4 [9823313.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1808-12 [9581817.001]
  • [Cites] Lancet. 1998 Mar 21;351(9106):882-3 [9525374.001]
  • [Cites] Phytochemistry. 1994 Jul;36(5):1287-91 [7765366.001]
  • [Cites] Semin Surg Oncol. 2003;21(2):122-7 [14508862.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 1;1644(2-3):229-49 [14996506.001]
  • [Cites] Cancer Immunol Immunother. 2004 Mar;53(3):153-9 [14749900.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 13;314(3):902-7 [14741722.001]
  • [Cites] J Nat Prod. 2004 Jan;67(1):2-4 [14738375.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Oct;126(4):1141-6 [14566260.001]
  • [Cites] Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S105-14 [14508087.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2003 Jul;51(7):790-3 [12843583.001]
  • [Cites] Fitoterapia. 2003 Jul;74(5):435-8 [12837357.001]
  • [Cites] Cancer Sci. 2003 Jan;94(1):15-21 [12708468.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2249-55 [12613509.001]
  • [Cites] Haematologica. 2003 Feb;88(2):212-8 [12604411.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Nov;50(5):343-52 [12439591.001]
  • [Cites] Planta Med. 2002 Oct;68(10):946-8 [12391566.001]
  • [Cites] Hum Gene Ther. 2002 Feb 10;13(3):415-23 [11860708.001]
  • [Cites] Oncogene. 2000 Mar 2;19(10):1346-53 [10713676.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):5991-4 [17947459.001]
  • (PMID = 19330074.001).
  • [ISSN] 1422-0067
  • [Journal-full-title] International journal of molecular sciences
  • [ISO-abbreviation] Int J Mol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC2635634
  • [Keywords] NOTNLM ; Bax / Bcl-2 / Leukemia / Ponicidin / Survivin
  •  go-up   go-down


37. Hussein MR, Al bshabshe AA, Dalati T: Leukemia cutis: case report and review of literature. Appl Immunohistochem Mol Morphol; 2010 Mar;18(2):190-1
MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia cutis: case report and review of literature.
  • Leukemias are neoplasms of hematolymphoid cells that predominantly involve the peripheral blood.
  • Cutaneous involvement (leukemia cutis) occurs in chronic myeloid leukemia, chronic lymphocytic leukemia, and in monocytic leukemia.
  • Here, we report a case of a 49-year-old female patient known to have chronic myeloid leukemia presented with multiple cutaneous lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19956066.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


38. Ferreri C, Kratzsch S, Brede O, Marciniak B, Chatgilialoglu C: Trans lipid formation induced by thiols in human monocytic leukemia cells. Free Radic Biol Med; 2005 May 1;38(9):1180-7
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trans lipid formation induced by thiols in human monocytic leukemia cells.
  • An endogenous path comprising a thiyl radical-catalyzed cis-trans isomerization of cis-unsaturated phospholipids was proposed.
  • Here we report the presence of trans lipids in human monocytic leukemia cell membranes (THP-1) before and after treatment with a 10 mM series of thiols.
  • These results offer the first evidence that trans lipids are formed in eukaryotic cells and confirm that thiyl radicals are harmful to the integrity of cis lipid geometry.
  • [MeSH-major] Leukemia / metabolism. Membrane Lipids / biosynthesis. Phospholipids / biosynthesis. Sulfhydryl Compounds / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15808415.001).
  • [ISSN] 0891-5849
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Lipids; 0 / Phospholipids; 0 / Sulfhydryl Compounds
  •  go-up   go-down


39. Altieri A, Castro F, Bermejo JL, Hemminki K: Number of siblings and the risk of lymphoma, leukemia, and myeloma by histopathology. Cancer Epidemiol Biomarkers Prev; 2006 Jul;15(7):1281-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Number of siblings and the risk of lymphoma, leukemia, and myeloma by histopathology.
  • Epidemiologic evidence indicates that several markers of exposure to childhood infections are inversely associated with the risk of childhood leukemia and lymphomas.
  • We used the Swedish Family-Cancer Database to assess the effects of number of siblings on the risk of non-Hodgkin's (n = 7,007) and Hodgkin's lymphomas (n = 3,115), leukemias (n = 7,650), and multiple myeloma (n = 1,492) by histopathology.
  • Having four or more siblings compared with none was associated with an excess risk of childhood acute lymphoblastic leukemia [ALL; rate ratio (RR), 2.11; P(trend) = 0.001], acute monocytic leukemia (RR, 2.51; P(trend) = 0.002), and multiple myeloma (RR, 1.34; P(trend) = 0.006).
  • Having three or more older siblings compared with none decreased the risk of acute monocytic leukemia (RR, 0.35; P(trend) = 0.001) and childhood ALL (RR, 0.69; P(trend) = 0.01).
  • Acute myeloid leukemia, chronic lymphocytic leukemia, and other lymphoproliferative malignancies were not associated with number of siblings.
  • In conclusion, we found an excess risk of childhood ALL and acute monocytic leukemia in large families.
  • However, for ALL, acute monocytic leukemia, and Hodgkin's lymphoma, younger siblings were strongly protected compared with older siblings.
  • The remarkable protective effect of number of older siblings on acute monocytic leukemia is a novel finding of potential interest.
  • [MeSH-major] Birth Order. Hodgkin Disease / etiology. Leukemia / etiology. Multiple Myeloma / etiology. Siblings

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835324.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


40. Li Z, Kustikova OS, Kamino K, Neumann T, Rhein M, Grassman E, Fehse B, Baum C: Insertional mutagenesis by replication-deficient retroviral vectors encoding the large T oncogene. Ann N Y Acad Sci; 2007 Jun;1106:95-113
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary hematopoietic stem/progenitor cells transduced with retroviral vectors encoding TAg-induced histiocytic sarcoma (HS) or myeloid leukemia (ML) in transplanted mice (average survival of 21 weeks).
  • Retrovirally introducing TAg into pretransformed 32D cells generated a monocytic leukemia, with faster kinetics ( approximately 8 weeks).
  • 32D-derived monocytic leukemias showed hits in Pim2 and Max proto-oncogenes, or the chaperone Hspa4, plus additional signaling genes.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17395733.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral, Tumor
  •  go-up   go-down


41. Villeneuve P, Kim DT, Xu W, Brandwein J, Chang H: The morphological subcategories of acute monocytic leukemia (M5a and M5b) share similar immunophenotypic and cytogenetic features and clinical outcomes. Leuk Res; 2008 Feb;32(2):269-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The morphological subcategories of acute monocytic leukemia (M5a and M5b) share similar immunophenotypic and cytogenetic features and clinical outcomes.
  • Acute monocytic leukemia (M5) is a subtype of acute myeloid leukemia (AML) with two distinct morphologic subcategories, M5a and M5b.
  • We compared the immunophenotype, cytogenetics and clinical outcome of AML M5 with non-M5 AML and also compared M5a with M5b.
  • One hundred and twelve M5 (76 M5a, 36 M5b) and 726 non-M5 cases were identified and treated on protocols at our institution.
  • Translocation 11q23 was the sole abnormality in 18.6% of M5 and 3.2% of non-M5 (p<0.001).
  • Trisomy 8 was also more prevalent in M5 (16.9%) than in non-M5 (8.7%; p=0.03).
  • The complete remission rate was 70% for AML M5 and 57% for non-M5 AML (p=0.03).
  • There was no significant difference in median overall survival or disease free survival for patients with M5 versus non-M5, M5a versus M5b.
  • Our data indicate that the prognosis of AML M5 is similar to non-M5 AML and that M5a and M5b do not differ in immunophenotype, cytogenetics or clinical outcome.
  • [MeSH-major] Leukemia, Monocytic, Acute / drug therapy. Leukemia, Monocytic, Acute / genetics. Leukemia, Monocytic, Acute / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689610.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


42. Peng B, Xu L, Cao F, Wei T, Yang C, Uzan G, Zhang D: HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way. Mol Cancer; 2010;9:79
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way.
  • In this study, we observed the effects of celastrol on the human monocytic leukemia cell line U937 cell cycle.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Drug Discov. 2008 Jul;7(7):608-24 [18591981.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5654-62 [18305216.001]
  • [Cites] J Cell Physiol. 2008 Dec;217(3):569-76 [18726991.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6704-11 [18927314.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8302-7 [19088048.001]
  • [Cites] Mini Rev Med Chem. 2009 Feb;9(2):140-52 [19200020.001]
  • [Cites] Cell Mol Biol Lett. 2009;14(2):319-35 [19183864.001]
  • [Cites] Drug Resist Updat. 2009 Feb-Apr;12(1-2):17-27 [19179103.001]
  • [Cites] Eur J Pharmacol. 2009 Jun 10;612(1-3):131-42 [19356729.001]
  • [Cites] Angew Chem Int Ed Engl. 2009;48(32):5853-5 [19585625.001]
  • [Cites] Mol Cancer Ther. 2009 Aug;8(8):2339-47 [19671767.001]
  • [Cites] Cytometry A. 2009 Dec;75(12):975-8 [19821513.001]
  • [Cites] J Biol Chem. 2009 Dec 18;284(51):35381-9 [19858214.001]
  • [Cites] Drug Discov Today. 2008 Jan;13(1-2):38-43 [18190862.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3940-6 [10919672.001]
  • [Cites] Clin Diagn Lab Immunol. 2001 Mar;8(2):397-401 [11238228.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1105-14 [12357246.001]
  • [Cites] Biosci Biotechnol Biochem. 2003 Sep;67(9):1883-7 [14519971.001]
  • [Cites] J Nat Prod. 2003 Nov;66(11):1416-20 [14640511.001]
  • [Cites] Biochemistry. 1993 Mar 16;32(10):2717-24 [8383523.001]
  • [Cites] Genes Dev. 1993 May;7(5):812-21 [8491378.001]
  • [Cites] J Biol Chem. 1996 Aug 23;271(34):20608-16 [8702807.001]
  • [Cites] Bioorg Med Chem Lett. 1998 Jul 21;8(14):1883-6 [9873452.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):2690-8 [10082535.001]
  • [Cites] BMC Neurosci. 2005;6:1 [15649316.001]
  • [Cites] Cancer Sci. 2005 Apr;96(4):240-4 [15819723.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8525-30 [15937123.001]
  • [Cites] J Endocrinol. 2006 Mar;188(3):481-92 [16522728.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4758-65 [16651429.001]
  • [Cites] Bioorg Med Chem Lett. 2006 Aug 15;16(16):4272-8 [16750360.001]
  • [Cites] J Leukoc Biol. 2006 Aug;80(2):309-19 [16769766.001]
  • [Cites] Br J Haematol. 2006 Oct;135(1):68-71 [16925576.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):321-30 [17010675.001]
  • [Cites] Biochem Pharmacol. 2006 Nov 15;72(10):1311-21 [16984800.001]
  • [Cites] ACS Chem Biol. 2006 Jun 20;1(5):279-84 [17163756.001]
  • [Cites] Mol Cancer Ther. 2008 Jan;7(1):162-70 [18202019.001]
  • [Cites] Bioorg Med Chem Lett. 2008 Feb 1;18(3):1050-2 [18164197.001]
  • [Cites] Mol Biol Cell. 2008 Mar;19(3):1104-12 [18199679.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Oct;62(5):769-78 [18193424.001]
  • (PMID = 20398364.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cell Cycle Proteins; 0 / HSP90 Heat-Shock Proteins; 0 / Sulfhydryl Compounds; 0 / Triterpenes; 34157-83-0 / tripterine
  • [Other-IDs] NLM/ PMC2873437
  •  go-up   go-down


43. Fan LP, Shen JZ, Fu HY, Zhou HR, Shen SF, Yu AF: [Effect of epigallocatechin-3-galate on human acute monocytic leukemia cell line U937 and its relevant mechanism]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr;18(2):286-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of epigallocatechin-3-galate on human acute monocytic leukemia cell line U937 and its relevant mechanism].
  • The purpose of this study was to explore the effect of epigallocatechin-3-galate (EGCG) on acute monocytic leukemia cell line U937 and its relevant mechanism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20416153.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA (cytosine-5-)-methyltransferase 1; EC 2.1.1.37 / DNA methyltransferase 3A; EC 2.1.1.37 / DNA methyltransferase 3B
  •  go-up   go-down


44. Katsumoto T, Yoshida N, Kitabayashi I: Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in normal and malignant hematopoiesis. Cancer Sci; 2008 Aug;99(8):1523-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in normal and malignant hematopoiesis.
  • The protein MOZ (monocytic leukemia zinc finger protein) is a Myst (MOZ, Ybf2 (Sas3), Sas2, Tip60)-type histone acetyltranseferase (HAT) that generates fusion genes, such as MOZ-TIF2, MOZ-CBP and MOZ-p300, in acute myeloid leukemia (AML) by chromosomal translocation.
  • [MeSH-major] Gene Fusion. Hematopoiesis / genetics. Histone Acetyltransferases / metabolism. Leukemia, Myeloid / metabolism

  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for monocytic leukemia .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18754862.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / KAT6A protein, human
  • [Number-of-references] 59
  •  go-up   go-down


45. Liu XD, Fan RF, Zhang Y, Yang HZ, Fang ZG, Guan WB, Lin DJ, Xiao RZ, Huang RW, Huang HQ, Liu PQ, Liu JJ: Down-regulation of telomerase activity and activation of caspase-3 are responsible for Tanshinone I-induced apoptosis in monocyte leukemia cells in vitro. Int J Mol Sci; 2010;11(6):2267-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of telomerase activity and activation of caspase-3 are responsible for Tanshinone I-induced apoptosis in monocyte leukemia cells in vitro.
  • In this study, we investigated the growth inhibition and apoptosis inducing effects of Tan-I on three kinds of monocytic leukemia cells (U937, THP-1 and SHI 1).
  • The results revealed that Tan-I could inhibit the growth of these three kinds of leukemia cells and cause apoptosis in a time- and dose-dependent manner.
  • We therefore conclude that the induction of apoptosis by Tan-I in monocytic leukemia U937 THP-1 and SHI 1 cells is highly correlated with activation of caspase-3 and decreasing of hTERT mRNA expression and telomerase activity as well as down-regulation of Survivin expression.
  • To our knowledge, this is the first report about the effects of Tan-I on monocytic leukemia cells.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Sci. 2003 Jan;94(1):15-21 [12708468.001]
  • [Cites] Mol Biosyst. 2008 Jun;4(6):629-42 [18493662.001]
  • [Cites] Curr Med Res Opin. 2003;19(6):470-2 [14594517.001]
  • [Cites] Ann Med. 2003;35(7):466-75 [14649329.001]
  • [Cites] Haematologica. 2003 Feb;88(2):212-8 [12604411.001]
  • [Cites] Leukemia. 2003 Mar;17(3):560-7 [12646945.001]
  • [Cites] Cancer Immunol Immunother. 2004 Mar;53(3):153-9 [14749900.001]
  • [Cites] Expert Opin Pharmacother. 2004 Dec;5(12):2485-501 [15571467.001]
  • [Cites] J Clin Pharmacol. 2005 Dec;45(12):1345-59 [16291709.001]
  • [Cites] J Cell Mol Med. 2005 Oct-Dec;9(4):977-89 [16364206.001]
  • [Cites] Oncogene. 2006 Sep 21;25(42):5719-25 [16652154.001]
  • [Cites] Leuk Res. 2007 Nov;31(11):1495-501 [17328950.001]
  • [Cites] Eur J Cancer Prev. 2008 Jun;17(3):209-17 [18414191.001]
  • [Cites] Exp Cell Res. 2008 Jun 10;314(9):1973-9 [18448098.001]
  • [Cites] Cancer Invest. 2008 Jul;26(6):590-6 [18584350.001]
  • [Cites] Leukemia. 2008 Jul;22(7):1410-8 [18449204.001]
  • [Cites] Int J Oncol. 2008 Sep;33(3):485-91 [18695877.001]
  • [Cites] Int J Mol Med. 2008 Nov;22(5):613-8 [18949381.001]
  • [Cites] Mol Cancer Ther. 2008 Nov;7(11):3527-38 [19001436.001]
  • [Cites] Cancer Treat Rev. 2009 Nov;35(7):553-62 [19559538.001]
  • [Cites] Curr Med Chem. 2010;17(15):1509-15 [20166933.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Jun;47(6):1836-41 [12760856.001]
  • (PMID = 20640151.001).
  • [ISSN] 1422-0067
  • [Journal-full-title] International journal of molecular sciences
  • [ISO-abbreviation] Int J Mol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / BIRC5 protein, human; 0 / Diterpenes, Abietane; 0 / Inhibitor of Apoptosis Proteins; 03UUH3J385 / tanshinone; EC 2.7.7.49 / Telomerase; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ PMC2904915
  • [Keywords] NOTNLM ; Tanshinone I (Tan-I) / leukemia / survivin / telomerase
  • [General-notes] NLM/ Original DateCompleted: 20110714
  •  go-up   go-down


46. Hattori T, Amano H, Nagai Y, Ishikawa O: Leukemia cutis in a patient with acute monocytic leukemia presenting as unique facial erythema. J Dermatol; 2008 Oct;35(10):671-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia cutis in a patient with acute monocytic leukemia presenting as unique facial erythema.
  • She had been diagnosed as having acute monocytic leukemia (French-American-British classification, M5b) based on the histological findings of bone marrow.
  • Specific cutaneous lesions could occur in acute monocytic leukemia more frequently than in other types of leukemia, but rarely show symmetrical edematous erythema limited to the face.
  • [MeSH-major] Erythema / diagnosis. Facial Dermatoses / diagnosis. Leukemia, Monocytic, Acute / pathology. Leukemic Infiltration / diagnosis. Skin / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19017048.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


47. Chantrain CF, Sauvage D, Brichard B, Dupont S, Poirel HA, Ameye G, De Weer A, Vandenberghe P, Detaille T, Anslot C, de Cléty SC, Vermylen C: Neonatal acute myeloid leukemia in an infant whose mother was exposed to diethylstilboestrol in utero. Pediatr Blood Cancer; 2009 Aug;53(2):220-2
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neonatal acute myeloid leukemia in an infant whose mother was exposed to diethylstilboestrol in utero.
  • We report on an acute myeloid leukemia in a neonate whose mother was exposed to diethylstilboestrol in utero.
  • The newborn presented with leukemia cutis, hemorrhagic skin lesions, hyperleucocytosis and disseminated intravascular coagulation.
  • A bone marrow examination confirmed the diagnosis of acute monocytic leukemia with a t(11;19) MLL-ELL fusion transcript.
  • This case shows acute myeloid leukemia and the third pediatric leukemia reported after maternal diethylstilboestrol exposure.
  • [MeSH-major] Diethylstilbestrol / adverse effects. Estrogens, Non-Steroidal / adverse effects. Leukemia, Myeloid, Acute / chemically induced. Prenatal Exposure Delayed Effects / chemically induced
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. In Situ Hybridization, Fluorescence. Infant, Newborn. Infertility, Female / chemically induced. Male. Mothers. Myeloid-Lymphoid Leukemia Protein. Oncogene Proteins, Fusion. Pedigree. Pregnancy. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19405140.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens, Non-Steroidal; 0 / MLL-ELL fusion protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


48. Noman AS, Koide N, Khuda II, Dagvadorj J, Tumurkhuu G, Naiki Y, Komatsu T, Yoshida T, Yokochi T: Thalidomide inhibits epidermal growth factor-induced cell growth in mouse and human monocytic leukemia cells via Ras inactivation. Biochem Biophys Res Commun; 2008 Oct 3;374(4):683-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalidomide inhibits epidermal growth factor-induced cell growth in mouse and human monocytic leukemia cells via Ras inactivation.
  • Thalidomide inhibited EGF-induced cell growth in mouse and human monocytic leukemia cells, RAW 264.7, U937 and THP-1.
  • There was no significant difference in the expression and function of EGF receptor between thalidomide-treated and non-treated cells.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Epidermal Growth Factor / antagonists & inhibitors. Leukemia / enzymology. Thalidomide / pharmacology. ras Proteins / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18662673.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Vascular Endothelial Growth Factor A; 4Z8R6ORS6L / Thalidomide; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


49. Li L, Zhang AH, Liu LB, Bi L, Wang L, Zhao YJ, Zou P: [Effect of down-regulating mll-af9 gene expression on proliferation of acute monocytic leukemia cell line THP-1]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr;16(2):254-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of down-regulating mll-af9 gene expression on proliferation of acute monocytic leukemia cell line THP-1].
  • This study was aimed to investigate the effect of small interfering RNA (siRNA) on the expression of mll-af9 oncogene and the proliferation of human acute monocytic leukemia cell line THP-1.
  • Then the obtained siRNA was transfected into cultured human acute monocytic leukemia cell line THP-1 by lipofectamine.
  • It is concluded that the mll-af9-targeted siRNA can effectively inhibit the proliferation of human acute monocytic leukemia cell line THP-1.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18426643.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / MLL-AF9 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  •  go-up   go-down


50. Kajiwara R, Goto H, Yanagimachi M, Kuroki F, Fujii H, Takahashi H, Yokota S: [Recurrent spontaneous regression of aleukemic leukemia cutis in a girl with acute monocytic leukemia]. Rinsho Ketsueki; 2006 Aug;47(8):764-9
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent spontaneous regression of aleukemic leukemia cutis in a girl with acute monocytic leukemia].
  • Aleukemic leukemia cutis is a rare form of leukemia manifestation, defined as a skin infiltration of leukemic cells with no evidence of leukemia in the bone marrow.
  • However, the diagnosis could not be made at that time.
  • Bone marrow aspiration revealed the predominance of monocytic blasts (76.4%), and the patient was diagnosed as having acute monocytic leukemia (M5b) with leukemia cutis.
  • [MeSH-major] Leukemia / diagnosis. Leukemia / etiology. Leukemia, Monocytic, Acute / complications. Neoplasm Regression, Spontaneous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16986716.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


51. Seo YI, Park R, Choi TY, Shin JW, Won JH, Park HS, Lee NS, Cho D: [A case of therapy-related acute monocytic leukemia following low-dose of etoposide treatment for hemophagocytic lymphohistiocytosis]. Korean J Lab Med; 2007 Aug;27(4):244-7
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of therapy-related acute monocytic leukemia following low-dose of etoposide treatment for hemophagocytic lymphohistiocytosis].
  • We report a case of therapy-related acute myeloid leukemia after low-dosed topoisomerase II inhibitor (etoposide) treatment for hemophagocytic lymphohistiocytosis (HLH).
  • Peripheral blood smear and bone marrow study revealed acute monocytic leukemia.
  • [MeSH-major] Etoposide / adverse effects. Leukemia, Monocytic, Acute / chemically induced. Leukemia, Monocytic, Acute / diagnosis. Lymphohistiocytosis, Hemophagocytic / drug therapy

  • Genetic Alliance. consumer health - Hemophagocytic Lymphohistiocytosis (HLH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094583.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


52. Liu Y, Sun ZG, Ren WC, Tian M, Li Y, Li CY: [Influences of Mycobacterium tuberculosis on the levels of human acute monocytic leukemia cell line THP-1 apoptosis and death]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Aug;31(4):417-22
Genetic Alliance. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Influences of Mycobacterium tuberculosis on the levels of human acute monocytic leukemia cell line THP-1 apoptosis and death].
  • OBJECTIVE: To explore the influences of Mycobacterium tuberculosis on the levels of human acute monocytic leukemia cell line THP-1 apoptosis and death.
  • METHODS: Human acute monocytic leukemia cell line THP-1 were infected with Mycobacterium tuberculosis strains H37Ra, H37Rv, or Beijing genotype (BJTB), respectively, to construct the infection models.
  • [MeSH-major] Leukemia, Monocytic, Acute. Mycobacterium tuberculosis / pathogenicity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19771726.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


53. McGrattan P, Logan A, Humphreys M, Bowers M: Jumping translocation in acute monocytic leukemia (M5b) with alternative breakpoint sites in the long arm of donor chromosome 3. Med Oncol; 2010 Sep;27(3):667-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Jumping translocation in acute monocytic leukemia (M5b) with alternative breakpoint sites in the long arm of donor chromosome 3.
  • After 20 months a diagnosis of disease transformation to acute monocytic leukemia (M5b) was made.
  • Conventional G-banded analysis of unstimulated peripheral blood cultures detected the proximal 3q1?2 JT clone involving recipient chromosome 10 several weeks after transformation to acute monocytic leukemia.
  • There have been fewer than 70 cases of acquired JTs reported in the literature, including one myeloproliferative neoplasm and five acute myeloid leukemias involving a single breakpoint site on donor chromosome 3.
  • [MeSH-major] Chromosome Breakpoints. Chromosomes, Human, Pair 3 / genetics. Leukemia, Monocytic, Acute / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Jan;14(1):119-22 [10637486.001]
  • [Cites] Leukemia. 2000 Sep;14(9):1630-3 [10995010.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1596-604 [17145595.001]
  • [Cites] Pathol Biol (Paris). 2007 Feb;55(1):37-48 [16697122.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Leukemia. 1998 Sep;12(9):1411-6 [9737690.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Apr 1;118(1):35-41 [10731588.001]
  • [Cites] Leukemia. 1995 Apr;9(4):634-9 [7723397.001]
  • [Cites] Leuk Res. 2004 Oct;28(10):1075-9 [15289020.001]
  • [Cites] Oncogene. 2007 Sep 6;26(41):5991-6001 [17369841.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Mar;109(2):144-9 [10087950.001]
  • [Cites] Br J Haematol. 2006 Jan;132(2):162-7 [16398650.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Jan 15;108(2):149-53 [9973944.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Aug;46(8):717-23 [17444494.001]
  • [Cites] Cancer Genet Cytogenet. 1988 Jul 1;33(1):29-33 [3164238.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Feb;51(2):189-94 [1993304.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] Cytogenet Cell Genet. 1988;48(4):224-7 [3248378.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Apr;24(4):295-8 [10092126.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Nov;71(1):22-6 [8275449.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Feb;109(1):40-4 [9973958.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1514-9 [9473214.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Oct 1;98(1):20-7 [9309114.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1732-41 [9473240.001]
  • (PMID = 19629764.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Park C, Kim GY, Kim GD, Lee WH, Cheong JH, Kim ND, Bae SJ, Jung JH, Choi YH: Suppression of U937 human monocytic leukemia cell growth by dideoxypetrosynol A, a polyacetylene from the sponge Petrosia sp., via induction of Cdk inhibitor p16 and down-regulation of pRB phosphorylation. Oncol Rep; 2006 Jul;16(1):171-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of U937 human monocytic leukemia cell growth by dideoxypetrosynol A, a polyacetylene from the sponge Petrosia sp., via induction of Cdk inhibitor p16 and down-regulation of pRB phosphorylation.
  • The aim of the present study was to further elucidate the possible mechanisms by which dideoxypetrosynol A exerts its anti-proliferative action in cultured human monocytic leukemia U937 cells.
  • [MeSH-major] Alkynes / pharmacology. Fatty Alcohols / pharmacology. Gene Expression Regulation, Neoplastic. Leukemia / drug therapy. Leukemia / pathology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. ACETYLENE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786142.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Alkynes; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / E2F Transcription Factors; 0 / Fatty Alcohols; 0 / Polymers; 0 / Retinoblastoma Protein; 0 / dideoxypetrosynol A; 25067-58-7 / Polyacetylenes; OC7TV75O83 / Acetylene
  •  go-up   go-down


55. Holbert MA, Sikorski T, Carten J, Snowflack D, Hodawadekar S, Marmorstein R: The human monocytic leukemia zinc finger histone acetyltransferase domain contains DNA-binding activity implicated in chromatin targeting. J Biol Chem; 2007 Dec 14;282(50):36603-13
Xenbase. Xenbase .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The human monocytic leukemia zinc finger histone acetyltransferase domain contains DNA-binding activity implicated in chromatin targeting.
  • The human monocytic leukemia zinc finger (MOZ) protein is an essential transcriptional coactivator and histone acetyltransferase (HAT) that plays a primary role in the differentiation of erythroid and myeloid cells and is required to maintain hematopoietic stem cells.
  • Chromosomal translocations involving the HAT-encoded region are also associated with acute myeloid leukemia.
  • We find that the HAT domain contains a central region that is structurally and functionally conserved with the yeast MYST HAT protein Esa1, but contains more divergent N- and C-terminal regions harboring a TFIIIA-type zinc finger and helix-turn-helix DNA-binding motifs.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925393.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Databank-accession-numbers] PDB/ 2RC4
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM060293; United States / NIGMS NIH HHS / GM / GM60293
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histones; 0 / Nucleosomes; 0 / Saccharomyces cerevisiae Proteins; 9007-49-2 / DNA; EC 2.3.1.48 / Esa1 protein, S cerevisiae; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / KAT6A protein, human
  •  go-up   go-down


56. Kurosu T, Tsuji K, Ohki M, Miki T, Yamamoto M, Kakihana K, Koyama T, Taniguchi S, Miura O: A variant-type MLL/SEPT9 fusion transcript in adult de novo acute monocytic leukemia (M5b) with t(11;17)(q23;q25). Int J Hematol; 2008 Sep;88(2):192-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A variant-type MLL/SEPT9 fusion transcript in adult de novo acute monocytic leukemia (M5b) with t(11;17)(q23;q25).
  • As a result of recurrent chromosomal translocations in acute leukemias, the mixed-lineage-leukemia (MLL) gene fuses with a variety of partner genes, which include several members of the septin gene family.
  • Herein, we report a case of de novo acute monocytic leukemia (M5b) with t(11;17)(q23;q25).
  • Relapsing after a very short complete remission, the leukemia progressed rapidly and became fatal in spite of intensive therapies including hematopoietic stem cell transplantation.
  • It is thus suggested that, in common with the original MLL/SEPT9 cases, monocytic differentiation and a poor prognosis may also be associated with acute myeloid leukemia with the variant MLL/SEPT9 fusion transcript.
  • [MeSH-major] GTP Phosphohydrolases / genetics. Leukemia, Monocytic, Acute / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2004 May;18(5):998-1005 [14999297.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):99-110 [12957285.001]
  • [Cites] Br J Haematol. 1996 Jun;93(4):966-72 [8703835.001]
  • [Cites] Oncogene. 2005 Jan 6;24(1):65-76 [15558029.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):919-29 [15761502.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):449-54 [15626757.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4688-700 [15782116.001]
  • [Cites] Blood. 1999 May 1;93(9):3074-80 [10216104.001]
  • [Cites] Genomics. 2000 Jan 15;63(2):165-72 [10673329.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Nov;45(11):1041-9 [16897742.001]
  • [Cites] Leukemia. 2004 Sep;18(9):1522-30 [15322560.001]
  • [Cites] Oncogene. 2006 Oct 5;25(45):6147-52 [16682951.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2434-9 [11290608.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55895-904 [15485874.001]
  • [Cites] Int J Hematol. 2005 Jul;82(1):9-20 [16105754.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4261-5 [10485469.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2484-90 [15956279.001]
  • [Cites] J Pathol. 2004 Nov;204(4):489-505 [15495264.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):6413-8 [9600980.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):197-207 [14522254.001]
  • [Cites] Int J Hematol. 2002 Jun;75(5):503-7 [12095151.001]
  • [Cites] Leukemia. 2006 Feb;20(2):218-23 [16341046.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):856-66 [16424018.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Sep;32(1):82-8 [11477664.001]
  • [Cites] Oncogene. 2001 Sep 13;20(41):5930-9 [11593400.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5695-707 [11607819.001]
  • [Cites] Eur J Clin Invest. 2004 Aug;34 Suppl 2:12-24 [15291802.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2179-87 [12727837.001]
  • [Cites] Leuk Res. 2007 Aug;31(8):1145-8 [17250889.001]
  • [Cites] J Pathol. 2003 Dec;201(4):581-8 [14648661.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6428-33 [10339604.001]
  • [Cites] Semin Hematol. 1999 Oct;36(4 Suppl 7):59-72 [10595755.001]
  • [Cites] Br J Haematol. 1999 Sep;106(3):614-26 [10468849.001]
  • [Cites] Gene. 2002 Feb 20;285(1-2):79-89 [12039034.001]
  • [Cites] Leukemia. 2006 May;20(5):777-84 [16511515.001]
  • (PMID = 18642054.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 3.6.1.- / GTP Phosphohydrolases; EC 3.6.1.- / SEPT9 protein, human; EC 3.6.1.- / Septins
  •  go-up   go-down


57. Huang JR, Wu CC, Hou RC, Jeng KC: Bromelain inhibits lipopolysaccharide-induced cytokine production in human THP-1 monocytes via the removal of CD14. Immunol Invest; 2008;37(4):263-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, we investigated the effect of bromelain on cytokine production from lipopolysaccharide (LPS)-stimulated human peripheral blood mononuclear cells (PBMC) and monocytic leukemia THP-1 cells.

  • Hazardous Substances Data Bank. BROMELAINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18569070.001).
  • [ISSN] 1532-4311
  • [Journal-full-title] Immunological investigations
  • [ISO-abbreviation] Immunol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD14; 0 / Cytokines; 0 / Interleukin-1; 0 / Interleukin-6; 0 / Lipopolysaccharides; 0 / NF-kappa B; 0 / Tumor Necrosis Factor-alpha; 9001-00-7 / Bromelains; EC 1.14.99.1 / Cyclooxygenase 2; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


58. Uchide N, Toyoda H: A new simple multi-well plate-based assay for monocyte differentiation using human monocytic leukemia THP-1 cells. J Immunol Methods; 2007 Dec 1;328(1-2):215-9
Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new simple multi-well plate-based assay for monocyte differentiation using human monocytic leukemia THP-1 cells.
  • The assay was conducted using a human monocytic leukemia cell line, THP-1, treated with either 12-O-tetradecanoylphorbol 13-acetate or cytokines, such as tumor necrosis factor-alpha and interferon-gamma.
  • [MeSH-minor] Cell Adhesion / drug effects. Cell Count / methods. Cell Proliferation. Humans. Interferon-gamma / pharmacology. Leukemia. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Scavenger Receptors, Class A / biosynthesis. Tetradecanoylphorbol Acetate / pharmacology. Tumor Necrosis Factor-alpha / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17920620.001).
  • [ISSN] 0022-1759
  • [Journal-full-title] Journal of immunological methods
  • [ISO-abbreviation] J. Immunol. Methods
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Scavenger Receptors, Class A; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


59. Ru YX, Mi YC, Liu JH, Cui W, Wang HJ, Zhao SX, Jian-Xiang W: Ribosome-lamella complex precursors in acute monocytic leukemia: a study of 6 cases. Ultrastruct Pathol; 2007 Mar-Apr;31(2):135-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ribosome-lamella complex precursors in acute monocytic leukemia: a study of 6 cases.
  • The ribosome-lamella complex (RLC) is a cylindrical structure composed of annular lamella associated particles, regarded as ribosomes, around a central core, which is best known in hairy cell leukemia.
  • The present paper investigates the various architectural aspects of pre-RLC and the ultrastructural characteristics of the blasts in 6 cases of acute monocytic leukemia (M5) in which these structures occur.
  • [MeSH-major] Cytoplasmic Granules / ultrastructure. Endoplasmic Reticulum, Rough / ultrastructure. Inclusion Bodies / ultrastructure. Intracellular Membranes / ultrastructure. Leukemia, Monocytic, Acute / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613993.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Li L, Wang J, Ye RD, Shi G, Jin H, Tang X, Yi J: PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: Mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase. J Cell Physiol; 2008 Nov;217(2):486-93
Hazardous Substances Data Bank. ARSENIC TRIOXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: Mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase.
  • Acute promyelocytic leukemia (APL) cells are characterized by PML/RARalpha fusion protein, high responsiveness to arsenic trioxide (ATO)-induced cytotoxicity and an abundant generation of reactive oxygen species (ROS).
  • We found that NADPH oxidase-derived ROS generation was more abundant in NB4 cells compared with monocytic leukemia U937 cells.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Arsenicals / pharmacology. Cyclic AMP / metabolism. Leukemia, Promyelocytic, Acute / enzymology. NADPH Oxidase / metabolism. Oncogene Proteins, Fusion / metabolism. Oxides / pharmacology. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc
  • (PMID = 18636556.001).
  • [ISSN] 1097-4652
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oncogene Proteins, Fusion; 0 / Oxides; 0 / Reactive Oxygen Species; 0 / promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; E0399OZS9N / Cyclic AMP; EC 1.6.3.1 / NADPH Oxidase; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


61. Thomas T, Corcoran LM, Gugasyan R, Dixon MP, Brodnicki T, Nutt SL, Metcalf D, Voss AK: Monocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cells. Genes Dev; 2006 May 1;20(9):1175-86
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cells.
  • Monocytic leukemia zinc finger protein (MOZ), a transcriptional coactivator and member of the MYST family of histone acetyltransferases, is the target of recurrent translocations in acute myeloid leukemia.
  • Since genes associated with translocations in leukemia are typically important regulators of blood formation, we investigated if Moz has a role in normal hematopoiesis.


62. Hulot C, Peluso J, Blond G, Muller CD, Suffert J: Synthesis of exotic polycycles such as cyclooctatrienes and fenestrenes with differential pro-apoptotic activities on human TRAIL-resistant metastatic cell lines. Bioorg Med Chem Lett; 2010 Nov 15;20(22):6836-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the 20 new compounds tested, two compounds presented specific activities on the colon carcinomas TRAIL-resistant metastatic cell SW620, but a minor action on the monocytic leukemia THP-1 cell line.
  • Six other compounds showed cell type specific activities: four induced apoptosis only in THP-1 cells and two only in SW620.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20864342.001).
  • [ISSN] 1464-3405
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Polycyclic Compounds; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human
  •  go-up   go-down


63. Brookhart MA, Rothman KJ: Simple estimators of the intensity of seasonal occurrence. BMC Med Res Methodol; 2008 Oct 22;8:67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We discuss various approaches to the estimation of seasonal intensity assuming Edwards's periodic model, including maximum likelihood estimation (MLE), least squares, weighted least squares, and a new closed-form estimator based on a second-order moment statistic and non-transformed data.
  • Finally, all estimators and confidence interval procedures discussed are compared in a re-analysis of data on the seasonality of monocytic leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Public Health. 2000 Jan;90(1):124-6 [10630151.001]
  • [Cites] Andrologia. 2002 Jun;34(3):194-203 [12059817.001]
  • [Cites] Br J Cancer. 2002 Aug 27;87(5):509-10 [12189545.001]
  • [Cites] Epidemiol Infect. 2002 Oct;129(2):361-9 [12403112.001]
  • [Cites] Epidemiology. 2002 Nov;13(6):734-7 [12410019.001]
  • [Cites] Ann Hum Genet. 1961 May;25:83-7 [13725808.001]
  • [Cites] Br J Prev Soc Med. 1971 Aug;25(3):174-6 [5564962.001]
  • [Cites] Br J Prev Soc Med. 1975 Mar;29(1):18-21 [1137765.001]
  • [Cites] Biometrics. 1988 Dec;44(4):1131-44 [3233250.001]
  • [Cites] Int J Epidemiol. 1996 Jun;25(3):644-8 [8671568.001]
  • [Cites] JAMA. 1997 Sep 24;278(12):1012-4 [9307350.001]
  • [Cites] Soc Sci Med. 2003 Oct;57(7):1173-81 [12899902.001]
  • (PMID = 18945366.001).
  • [ISSN] 1471-2288
  • [Journal-full-title] BMC medical research methodology
  • [ISO-abbreviation] BMC Med Res Methodol
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / K25 AG027400; United States / NIA NIH HHS / AG / AG-027400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2596789
  •  go-up   go-down


64. Johnson ES, Ndetan H, Lo KM: Cancer mortality in poultry slaughtering/processing plant workers belonging to a union pension fund. Environ Res; 2010 Aug;110(6):588-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Significantly increased risks were observed in the cohort as a whole or in subgroups, for several cancer sites, viz: cancers of the buccal cavity and pharynx; pancreas; trachea/bronchus/lung; brain; cervix; lymphoid leukemia; monocytic leukemia; and tumors of the hemopoietic and lymphatic systems.
  • What is needed now are epidemiologic studies that can demonstrate whether the excess of specific cancers can be attributed to specific occupational exposures while adequately controlling for other potential occupational and non-occupational carcinogenic exposures.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [ErratumIn] Environ Res. 2011 Jan;111(1):188-90
  • (PMID = 20541185.001).
  • [ISSN] 1096-0953
  • [Journal-full-title] Environmental research
  • [ISO-abbreviation] Environ. Res.
  • [Language] eng
  • [Grant] United States / NIOSH CDC HHS / OH / 1R01OH008071; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


65. Laengle UW, Markstein R, Cazaubon C, Roman D: Antiglaucoma drug GLC756 and its effect on cellular cAMP and tumor necrosis factor alpha release in vitro of activated human monocytic leukemia cells. Jpn J Ophthalmol; 2009 Mar;53(2):159-63
Hazardous Substances Data Bank. BETAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiglaucoma drug GLC756 and its effect on cellular cAMP and tumor necrosis factor alpha release in vitro of activated human monocytic leukemia cells.
  • The present study describes the effects of GLC756 on cellular adenosine 3', 5'-cyclic monophosphate (cAMP) in relation to TNF-alpha production on LPS-stimulated human acute monocytic leukemia cells.
  • METHODS: A human peripheral blood acute monocytic leukemia cell line (THP-1) was activated via LPS.
  • [MeSH-major] Antihypertensive Agents / pharmacology. Cyclic AMP / metabolism. Leukemia, Monocytic, Acute / drug therapy. Quinolines / pharmacology. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Front Biosci. 1997 Jan 01;2:d12-26 [9159205.001]
  • [Cites] Arthritis Res Ther. 2003;5(6):R317-28 [14680506.001]
  • [Cites] J Neuroimmunol. 2002 Nov;132(1-2):34-40 [12417431.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 1999;135:67-104 [9932481.001]
  • [Cites] Genome Biol. 2006;7(2):R11 [16507166.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Oct;279(4):L615-7 [11000119.001]
  • [Cites] Eur J Ophthalmol. 2006 May-Jun;16(3):401-6 [16761241.001]
  • [Cites] Cell Immunol. 1989 May;120(2):291-300 [2541929.001]
  • [Cites] J Invest Dermatol. 2005 Oct;125(4):783-9 [16185279.001]
  • [Cites] J Immunol. 1995 Nov 15;155(10):4909-16 [7594495.001]
  • [Cites] Neuroreport. 2000 Nov 9;11(16):3565-8 [11095519.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Oct;291(1):258-64 [10490912.001]
  • [Cites] J Immunol. 2002 Oct 1;169(7):3801-10 [12244175.001]
  • [Cites] Trends Pharmacol Sci. 1999 Feb;20(2):66-73 [10101967.001]
  • [Cites] J Neurochem. 2004 Apr;89(2):474-83 [15056290.001]
  • [Cites] Int Immunol. 2005 May;17 (5):599-606 [15802305.001]
  • [Cites] Infect Immun. 1989 Sep;57(9):2837-41 [2547721.001]
  • [Cites] J Ocul Pharmacol. 1992 Winter;8(4):285-94 [1484260.001]
  • [Cites] Crit Care Med. 1997 Nov;25(11):1855-61 [9366770.001]
  • [Cites] Gut. 1998 Apr;42(4):477-84 [9616307.001]
  • [Cites] Jpn J Ophthalmol. 1996;40(2):167-73 [8876383.001]
  • [Cites] Crit Rev Clin Lab Sci. 1999 Aug;36(4):275-328 [10486703.001]
  • [Cites] Eur J Immunol. 1996 Jul;26(7):1580-6 [8766564.001]
  • [Cites] Ophthalmology. 1989 Mar;96(3):327-35 [2710524.001]
  • [Cites] Clin Immunol Immunopathol. 1990 May;55(2):157-70 [2182227.001]
  • [Cites] Placenta. 2005 Sep-Oct;26(8-9):654-60 [16085044.001]
  • [Cites] Int J Immunopharmacol. 1993 Feb;15(2):219-28 [8096834.001]
  • [Cites] Int Ophthalmol. 1996-1997;20(1-3):57-62 [9112165.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1995 Jan;36(1):247-51 [7822153.001]
  • [Cites] Scand J Immunol. 1991 Jul;34(1):121-5 [1648785.001]
  • [Cites] Arch Ophthalmol. 1994 Nov;112(11):1437-45 [7980133.001]
  • [Cites] Exp Eye Res. 2006 Nov;83(5):1246-51 [16938291.001]
  • [Cites] J Neural Transm (Vienna). 1996;103(1-2):17-30 [9026371.001]
  • [Cites] Ophthalmology. 1995 Sep;102(9):1291-7 [9097765.001]
  • (PMID = 19333701.001).
  • [ISSN] 1613-2246
  • [Journal-full-title] Japanese journal of ophthalmology
  • [ISO-abbreviation] Jpn. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / Glucocorticoids; 0 / Lipopolysaccharides; 0 / Ophthalmic Solutions; 0 / Quinolines; 0 / Receptors, Dopamine D1; 0 / Receptors, Dopamine D2; 0 / SDZ GLC 756; 0 / Tumor Necrosis Factor-alpha; 9842X06Q6M / Betamethasone; E0399OZS9N / Cyclic AMP
  •  go-up   go-down


66. Sato Y, Yokoyama A, Shibata K, Akimoto Y, Ogino S, Nodasaka Y, Kohgo T, Tamura K, Akasaka T, Uo M, Motomiya K, Jeyadevan B, Ishiguro M, Hatakeyama R, Watari F, Tohji K: Influence of length on cytotoxicity of multi-walled carbon nanotubes against human acute monocytic leukemia cell line THP-1 in vitro and subcutaneous tissue of rats in vivo. Mol Biosyst; 2005 Jul;1(2):176-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of length on cytotoxicity of multi-walled carbon nanotubes against human acute monocytic leukemia cell line THP-1 in vitro and subcutaneous tissue of rats in vivo.
  • In this paper, we investigated the activation of the human acute monocytic leukemia cell line THP-1 in vitro and the response in subcutaneous tissue in vivo to CNTs of different lengths.
  • [MeSH-minor] Animals. Cell Line, Tumor. Culture Media / chemistry. Culture Media / pharmacology. Humans. Inflammation / etiology. Leukemia, Monocytic, Acute / metabolism. Leukemia, Monocytic, Acute / pathology. Male. Microscopy, Electron, Scanning. Microscopy, Electron, Transmission. Nanostructures / chemistry. Nanostructures / ultrastructure. Nanotechnology / methods. Rats. Rats, Wistar. Spectrophotometry, Infrared. Subcutaneous Tissue / pathology. Subcutaneous Tissue / ultrastructure. Tumor Necrosis Factor-alpha / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16880981.001).
  • [ISSN] 1742-206X
  • [Journal-full-title] Molecular bioSystems
  • [ISO-abbreviation] Mol Biosyst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Culture Media; 0 / Nanotubes, Carbon; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


67. Zhang GS, Peng HL, Dai CW, Gong FJ, Xu YX, Xiao L, Pei MF, Shen JK, Yang JJ: [Acute monocytic leukemia after orthotopic liver transplantation: clinical features, molecular genetics, and significance thereof]. Zhonghua Yi Xue Za Zhi; 2005 Dec 28;85(49):3504-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute monocytic leukemia after orthotopic liver transplantation: clinical features, molecular genetics, and significance thereof].
  • OBJECTIVE: To study the clinical features and molecular genetics of acute monocytic leukemia (AML) after orthotopic liver transplantation and significance thereof.
  • METHODS: The clinical manifestations, laboratory findings, development, diagnosis, treatment, and prognosis of the first case of AML after orthotopic liver transplantation in the world, a Chinese, male, aged 46, were observed.
  • The diagnosis of chronic myelomonocytic leukemia was made.
  • RT-PCR showed absence of wild type FLT3 allele.
  • At last the patient died of infection. (2) A FLT3-ITD mutation of "insertion" type was identified in the BMMCs.
  • CONCLUSION: Orthotopic liver transplantation may be complicated with acute leukemia heterogeneous in clinical features and hematology.
  • [MeSH-major] Leukemia, Monocytic, Acute / etiology. Leukemia, Monocytic, Acute / genetics. Liver Transplantation / adverse effects. Postoperative Complications

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686070.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HSP70 Heat-Shock Proteins; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3; EC 2.7.11.1 / PIM1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-pim-1
  •  go-up   go-down


68. Wu HJ, Chen Y: [Biological characteristics of hyperleukocytic acute leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun;14(3):450-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biological characteristics of hyperleukocytic acute leukemia].
  • The study was to investigate the biological characteristics of hyperleucocyte acute leukemia (HAL) and its clinical significance.
  • In AML, monocytic leukemia is easier to become into HAL than other leukemias.
  • In ALL, T-lineage antigens of HAL group are more easily expressed than those of NHAL group; the leukemia cells of HAL group are naiver than those of NHAL group, meanwhile the prognosis of HAL is poor.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800918.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD14; 0 / Antigens, CD79; 0 / Antigens, CD8; 0 / Sialic Acid Binding Ig-like Lectin 2
  •  go-up   go-down


69. Tsirigotis P, Papageorgiou S, Abatzis D, Athanatou S, Girkas C, Pappa V, Pangalos C, Papageorgiou E, Dervenoulas J, Raptis S: Acute myelogenous leukemia with tetrasomy 8 is a disease with a poor prognosis. Cancer Genet Cytogenet; 2005 Aug;161(1):78-81
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myelogenous leukemia with tetrasomy 8 is a disease with a poor prognosis.
  • Tetrasomy 8 is an extremely rare chromosome abnormality, one that has been reported in only a few cases with myeloid malignancies.
  • The majority of reported cases consist of acute myelogenous leukemias (AML) of monocytic lineage.
  • In slightly more than half of the patients, tetrasomy 8 was the single cytogenetic abnormality.
  • Here, we report the case of a 25-year-old female patient with monocytic leukemia and tetrasomy 8.
  • [MeSH-major] Aneuploidy. Chromosomes, Human, Pair 8 / genetics. Leukemia, Myeloid, Acute / genetics

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080962.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Bloise E, Braca A, De Tommasi N, Belisario MA: Pro-apoptotic and cytostatic activity of naturally occurring cardenolides. Cancer Chemother Pharmacol; 2009 Sep;64(4):793-802

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The pro-apoptotic and cytostatic effect of the compounds was tested in U937 (monocytic leukemia) and PC3 (prostate adenocarcinoma).
  • Interestingly, periplocymarin, at cytostatic but non-cytotoxic doses, was shown to sensitize U937 cells to TRAIL.
  • CONCLUSIONS: Taken together, our data outline that cardiac glycosides are promising anticancer drugs and contribute to the identification of new natural cardiac glycosides to obtain chemically modified non-cardioactive/low toxic derivatives with enhanced anticancer potency.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19184018.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cardenolides; 0 / DNA Primers; 0 / Enzyme Inhibitors; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase
  •  go-up   go-down


71. Wong KF, Yuen HL, Siu LL, Pang A, Kwong YL: t(8;16)(p11;p13) predisposes to a transient but potentially recurring neonatal leukemia. Hum Pathol; 2008 Nov;39(11):1702-7
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] t(8;16)(p11;p13) predisposes to a transient but potentially recurring neonatal leukemia.
  • A Chinese girl presented with generalized papular rash and monocytic leukemia 19 days after birth.
  • Cytogenetic analysis showed t(8;16)(p11.2;p13.3) as the sole chromosomal abnormality.
  • Spontaneous regression of the leukemia was observed after 2 months, although the t(8;16) translocation persisted cytogenetically.
  • This was followed 7 months later by the development of acute myeloid leukemia with maturation and cytogenetic evolution with extra chromosomes 4 and 8.
  • Molecular study showed that the reciprocal MYST3 and CREBBP gene fusion characteristic of t(8;16) translocation persisted throughout the clinical course, even during spontaneous regression of the neonatal leukemia, and after chemotherapy-induced remission of the subsequent acute myeloid leukemia.
  • The possible role of MYST3 and CREBBP gene fusion in the pathogenesis of the leukemia is discussed.
  • [MeSH-major] Leukemia, Monocytic, Acute / genetics. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18657848.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CREBBP protein, human; EC 2.3.1.48 / CREB-Binding Protein; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / KAT6A protein, human
  •  go-up   go-down


72. Wang Q, Li N, Wang X, Shen J, Hong X, Yu H, Zhang Y, Wan T, Zhang L, Wang J, Cao X: Membrane protein hMYADM preferentially expressed in myeloid cells is up-regulated during differentiation of stem cells and myeloid leukemia cells. Life Sci; 2007 Jan 9;80(5):420-9
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Membrane protein hMYADM preferentially expressed in myeloid cells is up-regulated during differentiation of stem cells and myeloid leukemia cells.
  • hMYADM is also closely related to many other eukaryotic proteins, which together form a novel and highly conserved MYADM-like family. hMYADM with 322-residue protein contains eight putative transmembrane segments and confocal microscopic analysis confirmed its membrane localization by using anti-hMYADM monoclonal antibody. hMYADM mRNA was selectively expressed in human monocytes, dendritic cells, promyeloid or monocytic leukemia cell lines, but not in CD4+, CD8+, CD19+ cells, nor in T cell leukemia or lymphocytic leukemia cell lines. hMYADM expression was also found in normal human bone marrow enriched for CD34+ stem cells, and the expression was up-regulated when these cells were induced to differentiate toward myeloid cells.
  • The mRNA expression level of hMYADM significantly increased in acute promyelocytic leukemia HL-60 and chronic myelogenous leukemia K562 cell line after phorbol myristate acetate (PMA)-induced differentiation.
  • Our study suggests that hMYADM is selectively expressed in myeloid cells, and involved in the myeloid differentiation process, indicating that hMYADM may be one useful membrane marker to monitor stem cell differentiation or myeloid leukemia differentiation.
  • [MeSH-major] Antigens, Differentiation / biosynthesis. Cell Differentiation. Cell Membrane / metabolism. Hematopoietic Stem Cells / metabolism. Leukemia, Myeloid / metabolism. Proteins / metabolism

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17097684.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY037147
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Differentiation; 0 / MYADM protein, human; 0 / Myadm protein, mouse; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / Proteins
  •  go-up   go-down


73. Liu ZR, Sun H, Zou P: [Expression of SDF-1alpha and its receptor CXCR4 in acute leukemias and their relationship with extramedullary infiltration]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb;14(1):1-5
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of SDF-1alpha and its receptor CXCR4 in acute leukemias and their relationship with extramedullary infiltration].
  • The study was aimed to explore the expression of stromal cell derived factor-1alpha (SDF-1alpha) and its receptor CXCR4, and their relationship with the extramedullary infiltration in acute lymphoblastic, grannulocytic and monocytic leukemia.
  • 66 cases of acute leukemia included 31 cases of acute lymphoblatic leukemia (ALL), 20 cases of acute grannulocytic leukemia (M(2)) and 15 cases of acute monocytic leukemia (M(4)+M(5)).
  • Enzyme-linked immunoabsorbent assay (ELISA) and flow cytometry were used to determine expression of SDF-1alpha and CXCR4 respectively on leukemia cells in peripheral blood and bone marrow of different groups.
  • It is concluded that the higher expression of CXCR4 on acute lymphoblatic and monocytic leukemia cells may be one of the molecular mechanisms of extramedullary infiltration in both kinds of leukemia.
  • The average plasma levels of SDF-1alpha decreased in leukemia patients and this decrease not related to the extramedullar infiltration, which may be due to the SDF-1alpha local expression in the organ infiltrated.

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16584580.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Receptors, CXCR4
  •  go-up   go-down


74. Sagawa M, Shimizu T, Shimizu T, Awaya N, Mitsuhashi T, Ikeda Y, Okamoto S, Kizaki M: Establishment of a new human acute monocytic leukemia cell line TZ-1 with t(1;11)(p32;q23) and fusion gene MLL-EPS15. Leukemia; 2006 Sep;20(9):1566-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of a new human acute monocytic leukemia cell line TZ-1 with t(1;11)(p32;q23) and fusion gene MLL-EPS15.
  • Human leukemia cell lines are of great value in investigating basic and applied aspects of cell biology and clinical medicine.
  • There have been 37 leukemia cell lines carrying 11q23 translocation and MLL rearrangements; however, cell lines harboring with t(1;11)(p32;q23) have not been established.
  • We report here for the first time a new acute monocytic leukemia (AMoL) cell line with t(1;11)(p32;q23), designated TZ-1, and herein describe its biological characteristics.
  • Mononuclear cells isolated from the ascites from a patient with AMoL (French-American-British classification; acute myeloid leukemia M5a) were isolated and passaged by liquid culture medium for a year.
  • TZ-1 cells revealed typical monocytic features in morphology and had a t(1;11)(p32;q23) translocation.
  • The immunoprofiling as determined by flow cytometry showed that TZ-1 cells are positive for myeloid and monocytic markers with lymphoid-associated markers.
  • Taken together, these results suggest that TZ-1 is a new monocytic leukemia cell line with t(1;11) translocation and fusion gene MLL-EPS15.
  • The established cell line, TZ-1, could provide a valuable model in the analysis of the pathogenesis of MLL-EPS15-positive leukemia and in the development of new agents for this type of leukemia.
  • [MeSH-major] Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 11. Leukemia, Monocytic, Acute / pathology. Translocation, Genetic

  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16826222.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


75. Ullah M, Pelletier N, Xiao L, Zhao SP, Wang K, Degerny C, Tahmasebi S, Cayrou C, Doyon Y, Goh SL, Champagne N, Côté J, Yang XJ: Molecular architecture of quartet MOZ/MORF histone acetyltransferase complexes. Mol Cell Biol; 2008 Nov;28(22):6828-43
Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The monocytic leukemia zinc finger protein MOZ and the related factor MORF form tetrameric complexes with ING5 (inhibitor of growth 5), EAF6 (Esa1-associated factor 6 ortholog), and the bromodomain-PHD finger protein BRPF1, -2, or -3.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2007 Aug 13;26(37):5385-94 [17694080.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5395-407 [17694081.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5408-19 [17694082.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5521-7 [17694091.001]
  • [Cites] Trends Biochem Sci. 2007 Nov;32(11):509-19 [17949986.001]
  • [Cites] Cell Growth Differ. 1996 Jul;7(7):917-22 [8809409.001]
  • [Cites] Blood. 1998 May 1;91(9):3127-33 [9558366.001]
  • [Cites] Blood. 1998 Sep 15;92(6):2118-22 [9731070.001]
  • [Cites] J Biol Chem. 1999 Oct 1;274(40):28528-36 [10497217.001]
  • [Cites] Cancer Cell. 2004 Dec;6(6):587-96 [15607963.001]
  • [Cites] Mol Cell Biol. 2007 Dec;27(24):8502-9 [17923702.001]
  • [Cites] J Biol Chem. 2007 Dec 14;282(50):36603-13 [17925393.001]
  • [Cites] Leukemia. 2008 Mar;22(3):663-5 [17805331.001]
  • [Cites] Development. 2008 Jun;135(11):1935-46 [18469222.001]
  • [Cites] Proteins. 2008 Sep;72(4):1371-6 [18623064.001]
  • [Cites] Mol Cell. 2006 Jan 6;21(1):51-64 [16387653.001]
  • [Cites] BMC Genomics. 2006;7:6 [16412250.001]
  • [Cites] Mol Cell Biol. 2006 Apr;26(8):3018-28 [16581777.001]
  • [Cites] Genes Dev. 2006 May 1;20(9):1175-86 [16651658.001]
  • [Cites] Genes Dev. 2006 May 15;20(10):1321-30 [16702405.001]
  • [Cites] Development. 2006 Jul;133(14):2661-9 [16774997.001]
  • [Cites] Oncogene. 1999 Dec 9;18(52):7442-52 [10602503.001]
  • [Cites] Development. 2000 Feb;127(4):713-23 [10648230.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jun;28(2):138-44 [10824998.001]
  • [Cites] Development. 2000 Jun;127(12):2537-48 [10821753.001]
  • [Cites] Microbiol Mol Biol Rev. 2000 Jun;64(2):435-59 [10839822.001]
  • [Cites] Mol Cell Biol. 2000 Sep;20(18):6904-12 [10958686.001]
  • [Cites] Hum Mol Genet. 2001 Feb 15;10(4):395-404 [11157802.001]
  • [Cites] Leukemia. 2001 Jan;15(1):89-94 [11243405.001]
  • [Cites] Curr Biol. 2001 Jan 23;11(2):99-104 [11231125.001]
  • [Cites] Oncogene. 2001 Jan 18;20(3):404-9 [11313971.001]
  • [Cites] EMBO J. 2001 Dec 17;20(24):7184-96 [11742995.001]
  • [Cites] Mol Cell. 2000 Nov;6(5):1195-205 [11106757.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2729-40 [11965546.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11836-41 [12189208.001]
  • [Cites] Trends Biochem Sci. 2003 Feb;28(2):69-74 [12575993.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):259-71 [12676584.001]
  • [Cites] Mol Cell. 2003 May;11(5):1265-77 [12769850.001]
  • [Cites] Nucleic Acids Res. 2003 Jun 1;31(11):2735-44 [12771199.001]
  • [Cites] Trends Genet. 2003 Jun;19(6):321-9 [12801725.001]
  • [Cites] Methods. 2003 Sep;31(1):24-32 [12893170.001]
  • [Cites] Genes Dev. 2003 Sep 1;17(17):2123-37 [12952888.001]
  • [Cites] Nucleic Acids Res. 2004;32(3):959-76 [14960713.001]
  • [Cites] Mol Cell Biol. 2004 Mar;24(5):1884-96 [14966270.001]
  • [Cites] Development. 2004 May;131(10):2443-61 [15128673.001]
  • [Cites] EMBO J. 2004 Jun 2;23(11):2258-68 [15141166.001]
  • [Cites] Electrophoresis. 2004 May;25(9):1327-33 [15174055.001]
  • [Cites] Curr Opin Genet Dev. 2004 Apr;14(2):147-54 [15196461.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5570-7 [15313893.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Feb 15;198(3):1143-52 [7906940.001]
  • [Cites] Mol Cell Biol. 1995 Apr;15(4):1858-69 [7891679.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):33-41 [8782817.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):42-9 [8782818.001]
  • [Cites] Mol Cell Biol. 2005 Feb;25(3):988-1002 [15657427.001]
  • [Cites] Mol Cell Biol. 2005 Mar;25(6):2273-87 [15743823.001]
  • [Cites] Nature. 2006 Jul 6;442(7098):96-9 [16728974.001]
  • [Cites] Nature. 2006 Jul 6;442(7098):100-3 [16728977.001]
  • [Cites] J Neurosci. 2006 Nov 1;26(44):11359-70 [17079664.001]
  • [Cites] Mol Cell. 2006 Dec 8;24(5):785-96 [17157260.001]
  • [Cites] FEBS Lett. 2006 Dec 22;580(30):6903-8 [17157298.001]
  • [Cites] Mol Cell. 2006 Dec 28;24(6):827-39 [17189186.001]
  • [Cites] Mol Cell. 2006 Dec 28;24(6):841-51 [17189187.001]
  • [Cites] Biochem J. 2007 Mar 15;402(3):559-66 [17083329.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Apr;8(4):284-95 [17380162.001]
  • [Cites] Cell Cycle. 2007 Mar 15;6(6):696-704 [17374998.001]
  • [Cites] Science. 2007 May 18;316(5827):1050-4 [17510366.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5341-57 [17694077.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5373-84 [17694079.001]
  • [ErratumIn] Mol Cell Biol. 2009 Feb;29(3):942
  • (PMID = 18794358.001).
  • [ISSN] 1098-5549
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] ENG
  • [Grant] None / None / / 64289-2; None / None / / 87253-1; Canada / Canadian Institutes of Health Research / / 64289-2; Canada / Canadian Institutes of Health Research / / 87253-1
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / BRPF1 protein, human; 0 / ING5 protein, human; 0 / Multiprotein Complexes; 0 / Nuclear Proteins; 0 / Protein Subunits; 0 / Recombinant Fusion Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / KAT6A protein, human; EC 2.3.1.48 / KAT6B protein, human
  • [Other-IDs] NLM/ PMC2573306
  •  go-up   go-down


76. Garcia C, Gardner D, Reichard KK: CD163: a specific immunohistochemical marker for acute myeloid leukemia with monocytic differentiation. Appl Immunohistochem Mol Morphol; 2008 Oct;16(5):417-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD163: a specific immunohistochemical marker for acute myeloid leukemia with monocytic differentiation.
  • Acute myeloid leukemias (AMLs) with monocytic differentiation with or without recurring cytogenetic abnormalities have prognostic significance.
  • Monocytic differentiation is identified by morphology and confirmed by cytochemical stains or flow cytometry.
  • Thus, the utility of CD163, a hemoglobin scavenger molecule present on monocytes/macrophages, in identifying a monocytic component in AML in fixed, paraffin-embedded bone marrows was assessed.
  • Using tissue microarrays, 31 cases of AML with monocytic differentiation and 35 cases without monocytic differentiation were evaluated in a blinded fashion for CD163 positivity and compared with CD68.
  • CD163 immunoreactivity was seen in 49% of AML cases with and 6% (2/35) without monocytic differentiation.
  • CD68 was positive in 81% of AML cases with and 17% without monocytic differentiation.
  • CD163 showed superior specificity for a monocytic component in AML compared with CD68 (94% vs. 83%).
  • However, the suboptimal sensitivity (49%) limits its utility as a definitive marker of monocytic differentiation if negative in paraffin sections.
  • These findings demonstrate that CD163 is helpful for the evaluation of a monocytic component in AML.
  • When positive, correlation and evaluation for an associated recurring cytogenetic abnormality is warranted.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18542032.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD163 antigen; 0 / CD68 antigen, human; 0 / Receptors, Cell Surface
  •  go-up   go-down


77. Hu XR, He JS, Ye XJ, Zheng WY, Wu WJ, Lin MF: Candida tropicalis arthritis in a patient with acute leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct;16(5):1215-8
MedlinePlus Health Information. consumer health - Yeast Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Candida tropicalis arthritis in a patient with acute leukemia.
  • A case of Candida tropicalis arthritis of knee occurred in a patient with acute monocytic leukemia was reported during the recovery phase of post chemotherapy myelosuppression and agranulocytosis.

  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Infectious Arthritis.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18928631.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


78. Krambeck FJ, Bennun SV, Narang S, Choi S, Yarema KJ, Betenbaugh MJ: A mathematical model to derive N-glycan structures and cellular enzyme activities from mass spectrometric data. Glycobiology; 2009 Nov;19(11):1163-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The method was applied to mass spectrometric data of normal human monocytes and monocytic leukemia (THP1) cells to derive glycosyltransferase activity changes underlying the differences in glycan structure between the normal and diseased cells.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1979 Nov 25;254(22):11655-63 [500665.001]
  • [Cites] Proteomics. 2004 Jun;4(6):1650-64 [15174134.001]
  • [Cites] J Biol Chem. 1989 Aug 25;264(24):14100-11 [2503511.001]
  • [Cites] Hum Pathol. 1990 Oct;21(10):1003-19 [2210723.001]
  • [Cites] Cancer Res. 1991 Feb 15;51(4):1257-63 [1997166.001]
  • [Cites] Glycobiology. 1997 Jun;7(4):515-21 [9184832.001]
  • [Cites] Acta Anat (Basel). 1998;161(1-4):36-78 [9780351.001]
  • [Cites] Proteomics. 2005 Mar;5(4):865-75 [15693066.001]
  • [Cites] Bioinformatics. 2005 Nov 1;21(21):3976-82 [16159923.001]
  • [Cites] Genome Biol. 2005;6(11):236 [16277754.001]
  • [Cites] Biotechnol Bioeng. 2005 Dec 20;92(6):711-28 [16247773.001]
  • [Cites] Biochim Biophys Acta. 2006 Apr;1760(4):568-77 [16459020.001]
  • [Cites] J Proteome Res. 2007 Oct;6(10):3995-4005 [17727280.001]
  • [Cites] Proteomics. 2008 Jan;8(1):8-20 [18095367.001]
  • [Cites] Genome Inform. 2007;18:237-46 [18546491.001]
  • [Cites] J Biochem. 2008 Jun;143(6):725-9 [18218651.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):21-34 [10580127.001]
  • [Cites] Biochimie. 2001 Aug;83(8):757-62 [11530208.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D431-3 [14681450.001]
  • [Cites] J Cell Biol. 1989 Feb;108(2):277-97 [2537312.001]
  • (PMID = 19506293.001).
  • [ISSN] 1460-2423
  • [Journal-full-title] Glycobiology
  • [ISO-abbreviation] Glycobiology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5R41CA127885-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Polysaccharides; EC 2.4.- / Glycosyltransferases
  • [Other-IDs] NLM/ PMC2757573
  •  go-up   go-down


79. Stahnke B, Thepen T, Stöcker M, Rosinke R, Jost E, Fischer R, Tur MK, Barth S: Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther; 2008 Sep;7(9):2924-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes.
  • Acute myeloid leukemia (AML) cells of subtypes M4 and M5 show enhanced expression of CD64 (FcgammaRI), the high-affinity receptor for IgG, which is normally expressed at high levels only on activated cells of the myeloid lineage.
  • [MeSH-major] Granzymes / pharmacology. Immunoglobulin Variable Region / pharmacology. Immunotoxins / pharmacology. Leukemia, Monocytic, Acute / metabolism. Receptors, IgG / antagonists & inhibitors. Recombinant Fusion Proteins / pharmacology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790773.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Variable Region; 0 / Immunotoxins; 0 / Receptors, IgG; 0 / Recombinant Fusion Proteins; EC 3.4.21.- / Granzymes; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


80. Amtmann E, Zöller M: Stimulation of CD95-induced apoptosis in T-cells by a subtype specific neutral sphingomyelinase inhibitor. Biochem Pharmacol; 2005 Apr 15;69(8):1141-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, T-cells (human T-cell lymphoma and PHA stimulated murine lymph node cells) and monocytic leukemia cells were lacking SMase activity at pH 8.0.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794934.001).
  • [ISSN] 0006-2952
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / C11AG compound; 0 / Cell Extracts; 0 / Guanidines; 0 / Phytohemagglutinins; EC 3.1.4.12 / Sphingomyelin Phosphodiesterase
  •  go-up   go-down


81. Kim JA, Kong CS, Kim SK: Effect of Sargassum thunbergii on ROS mediated oxidative damage and identification of polyunsaturated fatty acid components. Food Chem Toxicol; 2010 May;48(5):1243-9
Hazardous Substances Data Bank. HYDROGEN PEROXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment with S. thunbergii significantly reduced intracellular ROS mediated cell damage and inhibited myeloperoxidase (MPO) activity assessed in tumor necrosis factor-alpha (TNF-alpha) stimulated human monocytic leukemia in a concentration-dependent manner.
  • Furthermore, S. thunbergii contains polyunsaturated fatty acids such as arachidonic acid, arachidic acid, palmitic acid, elaidic acid, linoleic acid, stearic acid and cis-5,8,11,14,17-eicosanoic acid.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20171254.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Enzyme Inhibitors; 0 / Fatty Acids, Unsaturated; 0 / Fluoresceins; 0 / Oxidants; 0 / Plant Extracts; 0 / Reactive Oxygen Species; 2044-85-1 / diacetyldichlorofluorescein; BBX060AN9V / Hydrogen Peroxide; EC 1.- / Oxidoreductases; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


82. Wang C, Chen Z, Li Z, Cen J: The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells. Leuk Res; 2010 Aug;34(8):1083-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells.
  • The frequency of extramedullary infiltration (EMI) in acute myeloblastic leukemia (AML) is reported up to 40% and most prevalent in myelo-monoblastic and monoblastic subtypes of AML (M4 and M5 according to FAB classification).
  • To explore mechanism underlying EMI, we analyzed SHI-1 cells, a highly invasive human acute monocytic leukemia cell line, and found their strong expression of matrix metalloproteinase 2 (MMP-2), membrane type 1 MMP (MT1-MMP) and tissue inhibitor of metalloproteinase 2 (TIMP-2).
  • SHI-1 cells showed higher invasive ability to traverse reconstituted basement membranes (Matrigel) and stronger activation of proMMP-2 than other leukemia cell line such as NB4, K562, U937 and THP-1 cells.
  • [MeSH-major] Leukemia, Monocytic, Acute / metabolism. Leukemia, Monocytic, Acute / pathology. Matrix Metalloproteinase 14 / metabolism. Matrix Metalloproteinase 2 / metabolism. Tissue Inhibitor of Metalloproteinase-2 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20138666.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Laminin; 0 / Matrix Metalloproteinase Inhibitors; 0 / Proteoglycans; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 119978-18-6 / matrigel; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; 9007-34-5 / Collagen; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.80 / MMP14 protein, human; EC 3.4.24.80 / Matrix Metalloproteinase 14
  •  go-up   go-down


83. Horny HP, Sotlar K, Valent P: Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review. Pathobiology; 2010;77(4):169-80
Genetic Alliance. consumer health - Systemic mastocytosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnosis of systemic mastocytosis (SM) is mainly based on the morphological demonstration of compact mast cell infiltrates in various tissue sites.
  • Reliable immunohistochemical markers for the diagnosis and grading of SM have been established, but various differential diagnoses including myeloproliferative neoplasms, basophilic and eosinophilic leukemias may be very difficult to delineate.
  • Even more challenging is the recognition of hematological neoplasms with signs of mast cell differentiation but not fulfilling diagnostic criteria for SM, especially the rare myelomastocytic leukemia.
  • This hypogranulation can be regarded as cellular atypia and may lead to the misdiagnosis aspect of monocytic leukemia or histiocytic neoplasm.
  • There is increasing evidence that most patients with long-standing adult-type urticaria pigmentosa-like skin lesions have in fact indolent SM.
  • Therefore, such skin lesions are an important clue to the correct diagnosis in these patients.
  • However, in aggressive or leukemic SM skin lesions are usually absent and then the correct diagnosis relies on an appropriate investigation of bone marrow biopsy specimens using both SM-related immunohistochemical markers (tryptase, KIT, CD25, CD30) but also markers excluding potential differential diagnoses.
  • Investigation for presence of the activating KIT point mutation D816V is very helpful to establish a correct diagnosis of SM in all the difficult cases exhibiting a low degree of bone marrow infiltration or puzzling morphological findings.
  • [MeSH-major] Bone Marrow / pathology. Mastocytosis, Systemic / diagnosis
  • [MeSH-minor] Adult. Basophils / immunology. Basophils / pathology. Biopsy. Diagnosis, Differential. Humans. Mast Cells / immunology. Mast Cells / pathology. Myeloproliferative Disorders / diagnosis. Myeloproliferative Disorders / genetics. Myeloproliferative Disorders / immunology. Point Mutation. Urticaria Pigmentosa / diagnosis. Urticaria Pigmentosa / genetics. Urticaria Pigmentosa / pathology

  • Genetic Alliance. consumer health - Mast cell disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20616612.001).
  • [ISSN] 1423-0291
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


84. Takashi S, Park J, Fang S, Koyama S, Parikh I, Adler KB: A peptide against the N-terminus of myristoylated alanine-rich C kinase substrate inhibits degranulation of human leukocytes in vitro. Am J Respir Cell Mol Biol; 2006 Jun;34(6):647-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In additional studies using human leukocyte cell lines, secretion of eosinophil peroxidase from the eosinophil-like cell line HL-60 clone 15, lysozyme from the monocytic leukemia cell line U937, and granzyme from the lymphocyte natural killer cell line NK-92 were attenuated by preincubation of the cells with MANS but not with the missense control peptide.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Biol Med (Maywood). 2002 Sep;227(8):645-51 [12192108.001]
  • [Cites] Pharmacol Ther. 2005 Sep;107(3):358-76 [15951020.001]
  • [Cites] Physiol Rev. 2003 Apr;83(2):581-632 [12663867.001]
  • [Cites] J Immunol. 2003 May 15;170(10):5276-80 [12734377.001]
  • [Cites] J Allergy Clin Immunol. 2003 May;111(5):923-32; quiz 933 [12743551.001]
  • [Cites] J Biol Chem. 2003 Dec 5;278(49):48898-902 [14506265.001]
  • [Cites] Nat Med. 2004 Feb;10(2):193-6 [14716307.001]
  • [Cites] Blood. 2004 Aug 1;104(3):832-9 [15073033.001]
  • [Cites] Int J Cancer. 1976 May 15;17(5):565-77 [178611.001]
  • [Cites] J Immunol Methods. 1987 Nov 23;104(1-2):183-90 [3500234.001]
  • [Cites] Nature. 1988 Mar 24;332(6162):362-4 [3352735.001]
  • [Cites] Leuk Res. 1988;12(8):679-86 [3184985.001]
  • [Cites] J Exp Med. 1989 Jul 1;170(1):163-76 [2473157.001]
  • [Cites] Biochem J. 1990 Feb 15;266(1):195-200 [2138016.001]
  • [Cites] Blood. 2000 Feb 1;95(3):894-902 [10648401.001]
  • [Cites] J Allergy Clin Immunol. 2000 Apr;105(4):651-63 [10756213.001]
  • [Cites] Biochimie. 2000 Apr;82(4):339-52 [10865122.001]
  • [Cites] Am J Pathol. 2005 Sep;167(3):651-61 [16127146.001]
  • [Cites] J Hematother Stem Cell Res. 2001 Jun;10(3):369-83 [11454312.001]
  • [Cites] J Appl Physiol (1985). 2001 Aug;91(2):613-22 [11457772.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40982-90 [11533058.001]
  • [Cites] J Leukoc Biol. 2002 Apr;71(4):701-10 [11927658.001]
  • [Cites] Biochim Biophys Acta. 1990 Apr 9;1052(1):133-42 [2322590.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(15):5603-7 [2116001.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Dec;87(23):9472-6 [1979172.001]
  • [Cites] Nature. 1991 May 23;351(6324):320-2 [2034276.001]
  • [Cites] Nature. 1992 Apr 16;356(6370):618-22 [1560845.001]
  • [Cites] J Leukoc Biol. 1992 Aug;52(2):173-82 [1506773.001]
  • [Cites] Nature. 1993 Mar 25;362(6418):318-24 [8455717.001]
  • [Cites] Leukemia. 1994 Apr;8(4):652-8 [8152260.001]
  • [Cites] Biochim Biophys Acta. 1994 Sep 8;1223(2):267-73 [8086498.001]
  • [Cites] J Leukoc Biol. 1995 Jul;58(1):49-54 [7616105.001]
  • [Cites] Cell Immunol. 1995 Sep;164(2):234-9 [7656332.001]
  • [Cites] J Biol Chem. 1996 Aug 2;271(31):18797-802 [8702537.001]
  • [Cites] Blood. 1997 May 15;89(10):3503-21 [9160655.001]
  • [Cites] J Immunol. 1998 Feb 1;160(3):1385-92 [9570558.001]
  • [Cites] Blood. 1999 Jul 1;94(1):23-32 [10381494.001]
  • [Cites] J Immunol. 2003 Mar 1;170(5):2670-9 [12594296.001]
  • (PMID = 16543603.001).
  • [ISSN] 1044-1549
  • [Journal-full-title] American journal of respiratory cell and molecular biology
  • [ISO-abbreviation] Am. J. Respir. Cell Mol. Biol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R37 HL36982
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MARCKS-related peptide; 0 / Peptide Fragments; EC 1.11.1.- / Eosinophil Peroxidase; EC 1.11.1.7 / Peroxidase; EC 3.2.1.17 / Muramidase; EC 3.4.21.- / Granzymes; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.78 / GZMA protein, human; NI40JAQ945 / Tetradecanoylphorbol Acetate
  • [Other-IDs] NLM/ PMC2644225
  •  go-up   go-down


85. Lu J, Sheng GY, Zou X, Xu XJ, Zhao XM, Bai ST, Xu PR: [Effects of FMS-like tyrosine kinase 3 targeted RNA interference on proliferation and apoptosis of acute monocytic leukemia cell line THP-1]. Zhonghua Er Ke Za Zhi; 2007 Aug;45(8):615-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of FMS-like tyrosine kinase 3 targeted RNA interference on proliferation and apoptosis of acute monocytic leukemia cell line THP-1].
  • OBJECTIVE: FMS-like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase that is constitutively activated in (70-90)% pediatric patients with acute myeloid leukemia (AML) and appears to confer an adverse prognosis.
  • The aim of the present study was to investigate the efficacy of suppression of FLT3 induced by small hairpin interfering RNA (shRNA) on myeloproliferation and apoptosis in an acute monocytic leukemia (AMOL) cell line THP-1.
  • [MeSH-major] Apoptosis / drug effects. Cell Proliferation / drug effects. Leukemia, Monocytic, Acute / pathology. RNA, Small Interfering / pharmacology. fms-Like Tyrosine Kinase 3 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021537.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RNA, Small Interfering; EC 2.7.1.- / TYRO3 protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


86. Zhang C, Liang MY, Wang SM: [Clinical analysis of bicytopenia and pancytopenia during pregnancy]. Zhonghua Fu Chan Ke Za Zhi; 2009 Jul;44(7):488-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the diagnosis, management, pregnancy outcome and prognosis of bicytopenia or pancytopenia during pregnancy.
  • RESULTS: According to the clinical data and laboratory findings, the latter including complete blood cell count, reticulocyte count, peripheral smear, serum folate and vitamin B12 level, autoimmune antibody screening, bone marrow smear and biopsy, thirteen patients were diagnosed as having chronic aplastic anemia (CAA), six as having myelodysplastic syndromes (MDS), two as having megaloblastic anemia (MA), one as having paroxysmal nocturnal hemoglobinuria (PNH), one as having Evan's syndrome and one as having acute leukemia.
  • The patient with acute leukemia died of recurrence six months postpartum.
  • Of the 6 patients with MDS, one achieved partial remission, four no remission, and one transformed into acute monocytic leukemia, then refused chemotherapy and was lost follow-up.
  • Diagnosis should be made as soon as possible through appropriate and reasonable laboratory examinations.
  • [MeSH-major] Anemia, Aplastic / therapy. Blood Transfusion. Pancytopenia / therapy. Pregnancy Complications, Hematologic / diagnosis. Pregnancy Complications, Hematologic / therapy. Pregnancy Outcome
  • [MeSH-minor] Adult. Biopsy, Needle. Bone Marrow / pathology. Bone Marrow Examination. Female. Folic Acid / therapeutic use. Follow-Up Studies. Humans. Myelodysplastic Syndromes / diagnosis. Myelodysplastic Syndromes / pathology. Myelodysplastic Syndromes / therapy. Pregnancy. Prognosis. Retrospective Studies. Young Adult


87. Dunphy CH, Tang W: The value of CD64 expression in distinguishing acute myeloid leukemia with monocytic differentiation from other subtypes of acute myeloid leukemia: a flow cytometric analysis of 64 cases. Arch Pathol Lab Med; 2007 May;131(5):748-54
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of CD64 expression in distinguishing acute myeloid leukemia with monocytic differentiation from other subtypes of acute myeloid leukemia: a flow cytometric analysis of 64 cases.
  • CONTEXT: Flow cytometric immunophenotyping is a useful ancillary tool in the diagnosis and subclassification of acute myeloid leukemias (AMLs).
  • A recent study concluded that CD64 is sensitive and specific for distinguishing AMLs with a monocytic component (ie, AML M4 and AML M5) from other AML subtypes.
  • However, in that study, the intensity of CD64 was not well defined and the number of non-M4/non-M5 AMLs was small.
  • OBJECTIVE: To evaluate the usefulness of CD64 by flow cytometric immunophenotyping in distinguishing AMLs with monocytic differentiation from other AML subtypes.
  • [MeSH-major] Biomarkers, Tumor / analysis. Leukemia, Myeloid / diagnosis. Receptors, IgG / biosynthesis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488160.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / HLA-DR Antigens; 0 / Receptors, IgG
  •  go-up   go-down


88. Burvall K, Palmberg L, Larsson K: Organic dust-induced activation, adhesion to substrate and expression of intercellular adhesion molecules in THP-1 monocytes. Life Sci; 2007 Apr 3;80(17):1598-607
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study was aimed at investigating organic dust-induced activation of the monocytic leukemia cell line, THP-1.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320911.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Culture Media, Serum-Free; 0 / Dust; 0 / Membrane Glycoproteins; 0 / Receptors, Immunologic; 0 / SIGLEC1 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 1; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / Vimentin; 126547-89-5 / Intercellular Adhesion Molecule-1
  •  go-up   go-down


89. Gaurnier-Hausser A, Tuszynski GP: The immunomodulatory role of angiocidin, a novel angiogenesis inhibitor. Curr Pharm Des; 2009;15(17):1937-48
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have found that the monocytic leukemia cell line THP-1, as well as freshly isolated human peripheral blood monocytes, differentiate into macrophage-like cells when treated with angiocidin.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19519434.001).
  • [ISSN] 1873-4286
  • [Journal-full-title] Current pharmaceutical design
  • [ISO-abbreviation] Curr. Pharm. Des.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 88931
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Angiogenesis Inhibitors; 0 / Carrier Proteins; 0 / Cytokines; 0 / PSMD4 protein, human; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


90. Aires V, Hichami A, Filomenko R, Plé A, Rébé C, Bettaieb A, Khan NA: Docosahexaenoic acid induces increases in [Ca2+]i via inositol 1,4,5-triphosphate production and activates protein kinase C gamma and -delta via phosphatidylserine binding site: implication in apoptosis in U937 cells. Mol Pharmacol; 2007 Dec;72(6):1545-56
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated, in monocytic leukemia U937 cells, the effects of docosahexaenoic acid (DHA; 22:6 n-3) on calcium signaling and determined the implication of phospholipase C (PLC) and protein kinase C (PKC) in this pathway.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17878267.001).
  • [ISSN] 1521-0111
  • [Journal-full-title] Molecular pharmacology
  • [ISO-abbreviation] Mol. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phosphatidylserines; 25167-62-8 / Docosahexaenoic Acids; 85166-31-0 / Inositol 1,4,5-Trisphosphate; EC 2.7.1.- / protein kinase C gamma; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C-delta
  •  go-up   go-down


91. Kim HK, Kim JE, Chung J, Lee DS, Han KS, Park S, Cho HI: Plasma level of stromal derived factor-1 (SDF-1) is increased in disseminated intravascular coagulation patients who have poor outcomes: in vitro effect of SDF-1 on coagulopathy. Thromb Res; 2007;120(4):559-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SDF-1 did not affect the expression of surface TF protein and its function and the TF mRNA level in both monocytes and the monocytic leukemia cell line THP-1.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17239427.001).
  • [ISSN] 0049-3848
  • [Journal-full-title] Thrombosis research
  • [ISO-abbreviation] Thromb. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Thrombomodulin; 9035-58-9 / Thromboplastin
  •  go-up   go-down


92. Chen S, Xue Y, Zhang X, Wu Y, Pan J, Wang Y, Ceng J: A new human acute monocytic leukemia cell line SHI-1 with t(6;11)(q27;q23), p53 gene alterations and high tumorigenicity in nude mice. Haematologica; 2005 Jun;90(6):766-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new human acute monocytic leukemia cell line SHI-1 with t(6;11)(q27;q23), p53 gene alterations and high tumorigenicity in nude mice.
  • BACKGROUND AND OBJECTIVES: Human leukemia cell lines are of great value in leukemia research.
  • Thus far 36 leukemia cell lines carrying the 11q23 translocation and MLL rearrangements, including two cell lines with t(6;11)(q27;q23) and an MLL-AF6 fusion gene have been described.
  • We have established a new monocytic cell line with t(6;11), designated SHI-1, and herein describe its biological characteristics.
  • DESIGN AND METHODS: Mononuclear cells isolated from the bone marrow of a patient with acute monocytic leukemia (AML-M5b) at relapse were inoculated and passaged by liquid culture.
  • The morphology and immunoprofile of the cells show typical features of monocytic lineage.
  • Karyotypic analysis demonstrated a t(6;11)(q27;q23) translocation accompanied by a deletion of 17p, which are the same abnormalities as were seen in the leukemia cells of this patient in relapse.
  • The MLL-AF6 fusion transcript and the loss of one p53 allele were proven by chromosome painting, FISH and RT-PCR analysis in both SHI-1 cells and the primary leukemia cells.
  • A point mutation of ATC-->ACC at codon 195 of exon 6 in another p53 allele was found by direct sequencing of DNA in SHI-1 cells as well as in the primary leukemia cells.
  • INTERPRETATION AND CONCLUSIONS: SHI-1 is a new monocytic leukemia cell line with the t(6;11) translocation, p53 gene alterations, and high tumorigenicity in nude mice.
  • [MeSH-major] Cell Line, Tumor. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 6. Genes, p53. Leukemia, Monocytic, Acute / genetics. Translocation, Genetic

  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15951289.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


93. Cheng KC, Huang HC, Chen JH, Hsu JW, Cheng HC, Ou CH, Yang WB, Chen ST, Wong CH, Juan HF: Ganoderma lucidum polysaccharides in human monocytic leukemia cells: from gene expression to network construction. BMC Genomics; 2007;8:411
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ganoderma lucidum polysaccharides in human monocytic leukemia cells: from gene expression to network construction.
  • This gave rise to our investigation on how F3 stimulates immuno-modulating or anti-tumor effects in human leukemia THP-1 cells.
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Cytokines / genetics. Cytokines / metabolism. Enzyme-Linked Immunosorbent Assay. Gene Expression Profiling. Humans. Leukemia, Monocytic, Acute / genetics. Leukemia, Monocytic, Acute / metabolism. Leukemia, Monocytic, Acute / pathology. Oligonucleotide Array Sequence Analysis. Plant Extracts / chemistry. Plant Extracts / pharmacology. Polymerase Chain Reaction. Receptors, Death Domain / genetics. Receptors, Death Domain / metabolism. Signal Transduction / drug effects. Signal Transduction / genetics. Signal Transduction / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 Nov 4;402(6757):86-90 [10573422.001]
  • [Cites] Leuk Res. 2006 Jul;30(7):841-8 [16423392.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):823-6 [10866208.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):409-16 [11283615.001]
  • [Cites] J Biol Chem. 2001 Jan 26;276(4):2668-77 [11035039.001]
  • [Cites] Oncogene. 2001 Oct 4;20(45):6617-26 [11641787.001]
  • [Cites] Bioorg Med Chem. 2002 Apr;10(4):1057-62 [11836115.001]
  • [Cites] Cell Signal. 2002 Jun;14(6):477-92 [11897488.001]
  • [Cites] Nature. 2002 May 23;417(6887):399-403 [12000970.001]
  • [Cites] J Clin Immunol. 2002 Jul;22(4):185-94 [12148593.001]
  • [Cites] Electrophoresis. 2002 Aug;23(15):2490-504 [12210208.001]
  • [Cites] Int J Cancer. 2002 Nov 20;102(3):250-3 [12397644.001]
  • [Cites] Nat Rev Immunol. 2002 Nov;2(11):881-9 [12415311.001]
  • [Cites] Annu Rev Immunol. 2003;21:335-76 [12524386.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Apr;284(4):L663-70 [12495940.001]
  • [Cites] Cell Death Differ. 2003 Jan;10(1):45-65 [12655295.001]
  • [Cites] Cell Death Differ. 2003 Jan;10(1):66-75 [12655296.001]
  • [Cites] J Immunol. 2003 Aug 15;171(4):1941-9 [12902497.001]
  • [Cites] Cell Cycle. 2003 Nov-Dec;2(6):550-2 [14504472.001]
  • [Cites] Anal Chem. 2003 Nov 15;75(22):6163-70 [14615996.001]
  • [Cites] Leuk Res. 2004 Jan;28(1):63-9 [14630082.001]
  • [Cites] J Altern Complement Med. 2006 Oct;12(8):777-89 [17034284.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Nov 24;350(3):736-41 [17027647.001]
  • [Cites] Oncol Rep. 2006 Dec;16(6):1181-7 [17089035.001]
  • [Cites] Oncol Rep. 2006 Dec;16(6):1313-6 [17089055.001]
  • [Cites] Life Sci. 2006 Dec 23;80(3):205-11 [17007887.001]
  • [Cites] Cancer Lett. 2007 Feb 8;246(1-2):210-7 [16574319.001]
  • [Cites] Leuk Res. 2007 Apr;31(4):455-63 [16920192.001]
  • [Cites] Ann N Y Acad Sci. 2006 Dec;1090:209-16 [17384264.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4443-50 [17483359.001]
  • [Cites] Int J Oncol. 2004 May;24(5):1093-9 [15067330.001]
  • [Cites] Bioinformatics. 2004 Jun 12;20(9):1453-4 [14871861.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W460-4 [15215430.001]
  • [Cites] Bioorg Med Chem. 2004 Nov 1;12(21):5595-601 [15465337.001]
  • [Cites] Phytother Res. 2004 Sep;18(9):768-70 [15478180.001]
  • [Cites] Cancer Lett. 2004 Dec 8;216(1):9-20 [15500944.001]
  • [Cites] Cell. 1994 Mar 25;76(6):959-62 [8137429.001]
  • [Cites] Blood. 1994 Apr 15;83(8):2045-56 [8161776.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 May 26;95(11):5849-56 [9600883.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1305-8 [9721089.001]
  • [Cites] Trends Biochem Sci. 1998 Sep;23(9):324-8 [9787636.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2896-901 [10077608.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4285-8 [10200254.001]
  • [Cites] Curr Opin Cell Biol. 1999 Apr;11(2):255-60 [10209153.001]
  • [Cites] Science. 1999 Jul 30;285(5428):751-3 [10427000.001]
  • [Cites] J Immunol. 2004 Nov 15;173(10):5989-99 [15528333.001]
  • [Cites] Mini Rev Med Chem. 2004 Oct;4(8):873-9 [15544548.001]
  • [Cites] Apoptosis. 2005 Jan;10(1):35-51 [15711921.001]
  • [Cites] Cancer Lett. 2005 Mar 18;220(1):21-8 [15737684.001]
  • [Cites] Genome Biol. 2005;6(3):211 [15774034.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Apr 29;330(1):46-52 [15781230.001]
  • [Cites] Bioinformatics. 2005 Apr 1;21(7):1180-8 [15513993.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12837-42 [16141318.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10214-22 [16288009.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):274-87 [16365179.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] Exp Oncol. 2006 Mar;28(1):25-9 [16614703.001]
  • [Cites] J Biol Chem. 2006 Aug 25;281(34):24111-23 [16798741.001]
  • [Cites] Nat Genet. 2000 May;25(1):25-9 [10802651.001]
  • (PMID = 17996095.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Drugs, Chinese Herbal; 0 / Plant Extracts; 0 / Polysaccharides; 0 / Receptors, Death Domain
  • [Other-IDs] NLM/ PMC2211495
  •  go-up   go-down


94. Lee YN, Lee HY, Kim JS, Park C, Choi YH, Lee TG, Ryu SH, Kwak JY, Bae YS: The novel phospholipase C activator, m-3M3FBS, induces monocytic leukemia cell apoptosis. Cancer Lett; 2005 May 26;222(2):227-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The novel phospholipase C activator, m-3M3FBS, induces monocytic leukemia cell apoptosis.
  • [MeSH-major] Apoptosis / drug effects. Leukemia, Monocytic, Acute / pathology. Sulfonamides / pharmacology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863272.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / 2,4,6-trimethyl-N-(meta-3-trifluoromethylphenyl)benzenesulfonamide; 0 / BAX protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Sulfonamides; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


95. Zhou FL, Zhang WG, Meng X, Chen G, Wang JL: [Bioinformatic analysis and identification for a novel antigen MLAA-22 in acute monocytic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun;16(3):466-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bioinformatic analysis and identification for a novel antigen MLAA-22 in acute monocytic leukemia].
  • The MLAA-22 encoded a cancer/testis antigen in human, which is nonsecreting type, plasmosin, labile protein, hydrophilia, thermostability, and without signal peptide.
  • It is concluded that mlaa-22 is a novel acute monocytic leukemia-associated antigen gene and be extended to further discovery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18549609.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Epitopes; 0 / KIAA0100 protein, human; 0 / Neoplasm Proteins
  •  go-up   go-down


96. Wang YF, Song QS, Zhang YM, Ma DL, Wang Y, Ke XY: [Sensitizing effect of recombinant human PDCD5 protein on chemotherapy of acute monocytic leukemia cell line U937 and its mechanism]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr;18(2):277-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sensitizing effect of recombinant human PDCD5 protein on chemotherapy of acute monocytic leukemia cell line U937 and its mechanism].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20416151.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Neoplasm Proteins; 0 / PDCD5 protein, human; 0 / Recombinant Proteins; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


97. Li ZJ, Chen ZX, Cen JN, He J: [Overexpression of tissue inhibitor of metalloprotease-2 promotes proliferation and infiltration of human monocytic leukemia cells]. Zhonghua Yi Xue Za Zhi; 2006 Sep 12;86(34):2409-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Overexpression of tissue inhibitor of metalloprotease-2 promotes proliferation and infiltration of human monocytic leukemia cells].
  • OBJECTIVE: To investigate the functional role of human tissue inhibitor of metalloprotease (TIMP)-2 gene on the proliferation and infiltrating capability of human monocytic leukemic cells.
  • METHODS: Human monocytic leukemic cells of the line SHI-1 were cultured and the TIMP-2 expression on the cell membrane was detected by flow cytometry (FCM).
  • Human bone marrow matrix cells (BMMC) of leukemia patient and SHI-1/TIMP-2 cells or SHI-1/MSCV cells were put into the upper layers as experimental groups, and SHI-1/TIMP-2 cells or SHI-1/MSCV cells only, without human BMMC, were put into the upper layers as control groups.
  • Thirty days later 8 mice from each group were killed to observe the tumorigenesis in the organs, especially the central nervous system leukemia (CNL).
  • [MeSH-major] Cell Membrane / metabolism. Cell Proliferation. Leukemia, Monocytic, Acute / metabolism. Leukemia, Monocytic, Acute / pathology. Tissue Inhibitor of Metalloproteinase-2 / biosynthesis
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Survival. Flow Cytometry. Humans. Leukemia, Experimental / genetics. Leukemia, Experimental / metabolism. Leukemia, Experimental / pathology. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Invasiveness. Neoplasm Transplantation / methods. Transfection. Transplantation, Heterologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17156653.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2
  •  go-up   go-down


98. Yamamoto M, Hirano S, Vogel CF, Cui X, Matsumura F: Selective activation of NF-kappaB and E2F by low concentration of arsenite in U937 human monocytic leukemia cells. J Biochem Mol Toxicol; 2008 Mar-Apr;22(2):136-46
Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective activation of NF-kappaB and E2F by low concentration of arsenite in U937 human monocytic leukemia cells.
  • Arsenite has been reported to exert dose-dependent dual effects: triggering apoptosis at relatively high concentrations, whereas inducing partial differentiation at low concentrations in leukemia cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 Wiley Periodicals, Inc.
  • (PMID = 18418899.001).
  • [ISSN] 1099-0461
  • [Journal-full-title] Journal of biochemical and molecular toxicology
  • [ISO-abbreviation] J. Biochem. Mol. Toxicol.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / ES05233; United States / NIEHS NIH HHS / ES / ES05707
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenites; 0 / DNA Primers; 0 / E2F Transcription Factors; 0 / NF-kappa B; 0 / RNA, Messenger; N5509X556J / arsenite; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


99. Kuo CC, Kuo CW, Liang CM, Liang SM: A transcriptomic and proteomic analysis of the effect of CpG-ODN on human THP-1 monocytic leukemia cells. Proteomics; 2005 Mar;5(4):894-906
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A transcriptomic and proteomic analysis of the effect of CpG-ODN on human THP-1 monocytic leukemia cells.
  • [MeSH-major] CpG Islands. Gene Expression Regulation, Neoplastic. Genetic Therapy / methods. Leukemia, Monocytic, Acute / therapy. Oligonucleotides / genetics. Proteomics / methods. Transcription, Genetic

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693060.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Oligonucleotides; 0 / RNA, Messenger; 20350-15-6 / Brefeldin A; EC 1.13.12.- / Luciferases; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


100. Zhou B, Ju SG, Ju SW, Xie F, Zhang XG: [Establishment of human acute monocytic leukemia model in severe combined immunodeficient (SCID) mice and the analysis of pathological changes]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Jun;23(6):501-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Establishment of human acute monocytic leukemia model in severe combined immunodeficient (SCID) mice and the analysis of pathological changes].
  • AIM: To establish a model of human M5 leukemia and investigate the pathomorphological change in severe combined immunodeficient (SCID) mice after being transplanted with SHI-1 cells.
  • CONCLUSION: The SHI-1/SCID mice was constructed, which provided a useful tool to investigate acute monocytic leukemia(AML).
  • [MeSH-major] Leukemia, Monocytic, Acute / metabolism. Leukemia, Monocytic, Acute / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17553342.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / 4-1BB Ligand; 0 / Antigens, CD14
  •  go-up   go-down






Advertisement